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Abstract
The HIV-1 envelope glycoproteins gp120 and gp41 mediate binding and fusion of
the virus to target cells. The envelope glycoproteins are exposed on the surface of the
virus as trimeric spikes and are the major targets for neutralizing antibodies. The design
of envelope glycoprotein-based subunit vaccines has been frustrated by many viral
immune escape mechanisms. Trimeric envelope glycoprotein formulations hold promise
to overcome limitations of monomeric envelope glycoproteins as immunogens. The
generation of native, trimeric envelope glycoprotein complexes, however, remains a
major challenge.
Here, solid-phase proteoliposomes containing native, trimeric HIV-1 envelope
glycoprotein complexes that mimic the trimeric complex as it is found on the viral
surface have been designed. In a comparative immunogenicity study, these
proteoliposomes were shown to better elicit broadly neutralizing antibodies than gp120.
A second trimeric envelope glycoprotein formulation, soluble YU2 gp140-GCN4
constructs, were also shown to better elicit broadly neutralizing antibodies in rabbits,
extending a previous study in mice. These data support the hypothesis that trimeric
envelope glycoprotein formulations are an advance over gp120-based immunogens.
To date, only four broadly neutralizing antibodies against the HIV-1 envelope
glycoproteins have been identified. Here, three novel Fab antibody fragments binding to
the CD4 binding site of gp120 have been identified from phage-displayed antibody
libraries with proteoliposomes. These Fab antibodies display some breadth and potency
in neutralizing HIV-1. Comparison of the neutralizing activity of Fab antibodies and
whole antibodies directed to the CD4 binding site suggests that these Fab antibodies may
significantly gain neutralizing potency as whole antibodies.
Many HIV-1 immune escape mechanisms complicate the elicitation of broadly
neutralizing antibodies. Core gp120 envelope glycoproteins derived from primary isolate
viruses were found to be deficient in T-helper epitopes. This finding is suggestive of yet
another HIV-1 viral immune escape mechanism, the escape from recognition by CD4+ T-
helper cells.
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1 Introduction
1.1 AIDS
Since the first reported cases of acquired immune deficiency syndrome (AIDS) in
1981, AIDS has become a pandemic of catastrophic proportions. Human
immunodeficiency viruses (HIV) type 1 and type 2 are the etiologic agents of AIDS (10,
43). According to UNAIDS, there are an estimated 40 million people living with HIV
today, predominantly of the HIV-1 type. In sub-Saharan Africa, AIDS is today the
leading cause of death. The adult prevalence in many of these countries exceeds 10%.
Eastern Europe and China are presently experiencing the steepest increase in new
infections and may only be at the beginning of a disastrous epidemic.
With the availability of highly active anti-retroviral therapy (HAART), the
progression of HIV-infection to AIDS can be slowed. However, while 500,000 people
received HAART and 25,000 people died of AIDS or related diseases in the developed
world last year, in sub-Saharan Africa, only 30,000 people received HAART and 2.3
million people died (www.unaids.org). The high cost of antiviral therapies and the
complexities of their administration make it unlikely that these drugs will significantly
alter the course of the HIV epidemic in developing areas of the world. Only a broadly
effective vaccine will eventually be able to curb the global spread of HIV.
HIV infects and depletes primarily CD4+ T-helper cells. HIV infection typically
progresses through three stages: Acute, latent and AIDS (39). During the acute phase, a
burst of viral replication coincides with rapid loss of CD4+ T-helper cells. The end of the
acute phase, which occurs within a few weeks of infection, is characterized by a drop in
viral load and a rebounding CD4+ T-helper cell count. During the subsequent latent
phase, constant turnover of virus and CD4+ T-helper cells occurs, resulting in a slow and
gradual decline in CD4+ T-helper cells. Eventually, the loss of CD4+ T-helper cells
becomes too severe and leads to the failure of the immune system to fend off pathogens
that do not generally pose a threat to immunocompetent individuals. The emergence of
opportunistic infections such as Pneumocystis carinii, cytomegalovirus, or neoplasms
such as Karposi’s sarcoma mark the onset of AIDS. Without treatment, AIDS patients
rarely survive longer than a few years.
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1.2 HIV
HIV belongs to the genus lentivirinae of the Retroviridae family. Based on
sequence analysis and serologic properties, two types of HIV have been identified. HIV-1
is the prevalent strain in Africa, Asia, Europe, North- and South America. In some West
African countries, HIV-2 is the dominant strain. Genetically related viruses that infect
nonhuman primates, the simian immunodeficiency viruses (SIV), have been isolated and
are believed to have given rise to HIV by cross-species transmission. In fact, HIV-1
exhibits more sequence homology to an SIV found in chimpanzees than it does to HIV-2.
HIV-2, in turn, is most closely related to SIV isolated from sooty mangabeys (24, 42).
FIG. 1. Schematic diagram of the HIV-1 genome and its gene products. Virion structural genes are
depicted as shaded, accessory genes as clear boxes (from Fields, Fundamental Virology). MA: Matrix
protein, CA: Capsid protein, NC: Nucleocapsid protein, PR: Protease, RT: Reverse transcriptase, IN:
Integrase, SU: Surface glycoprotein (gp120), TM: Transmembrane glycoprotein (gp41).
HIV is an enveloped virus with two identical copies of a single-stranded RNA
genome of about 9.2 kb. The HIV genome encodes nine genes (gag, pol, env, tat, rev, vif,
vpr, vpu, and nef) in three open reading frames. It is flanked on either side by identical
long terminal repeats (LTRs) that contain non-coding sequences important for viral
replication (Fig. 1). After entry of the virus into the host cell, the RNA genome is
reverse-transcribed by viral reverse transcriptase and the provirus is integrated into the
host genome by the viral integrase. The first viral gene products to be expressed by host-
cell RNA polymerases are Tat and Rev, which upregulate the subsequent expression of
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structural proteins. While Gag and Gag-Pol become localized to the inner surface of the
plasma membrane, Env is extensively modified in the endoplasmic reticulum. The Gag
and Gag-Pol polyproteins assemble the core particle containing genomic RNA and the
accessory protein Vpr. The viral particle then buds from the cell surface, acquiring in the
process a membrane containing envelope glycoprotein complexes. After budding,
proteolytic processing of Gag and Gag-Pol by the viral protease generates the mature,
fully infectious virus (38).
1.3 The HIV-1 envelope glycoproteins: Structure and function
The HIV-1 envelope glycoproteins gp120 and gp41 facilitate binding of the virus
to its target cell and mediate fusion between viral and cellular membranes (121). Initially,
the envelope glycoproteins are synthesized as highly glycosylated gp160 polyprotein
precursors that undergo a sequence of additional posttranslational modifications (3, 36,
85). After oligomerization in the endoplasmic reticulum, the polyprotein is cleaved into
the gp120 and gp41 subunits by cellular proteases. The envelope glycoproteins remain
associated through noncovalent interactions. They are extensively glycosylated and
transported to the plasma membrane. From there, the envelope glycoprotein complexes
are incorporated into budding virions. Many lines of evidence suggest that the mature,
functional envelope glycoprotein complex on the viral surface consists of a trimer of
gp120-gp41 heterodimers. The ectodomain of HIV-1 gp41 crystallizes as a trimeric
coiled coil with interdigitating alpha helices to form a six-helix bundle (25, 109, 116).
The structure of the simian immunodeficiency virus (SIV) ectodomain has been solved
by magnetic resonance and shown to be trimeric (22). Both the HIV-1 and SIV
postfusogenic states of gp41 share close resemblance with the corresponding
transmembrane proteins of viruses such as influenza (19) and Ebola virus (115). Each of
these fusion determinants has been crystallized as helical bundles possessing trimeric
coiled-coil motifs. The matrix proteins of HIV-1 and SIV that interact with gp41 also
crystallize as trimers (48). The gp160 ectodomain of SIV (gp140) has been shown to be
trimeric by biophysical analysis (26). Trimerization has also been reported for a number
of gp120-gp41/gp140 ectodomain constructs (14, 122, 124).
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FIG. 2. Molecular surface presentation of HIV-1 core gp120 (from Wyatt and Sodroski, 1998). A. The
arrow indicates the direction of the viral membrane. The inner domain is facing towards the left, and the
outer domain, which is thought to be exposed on the assembled trimer, is on the right. The red surface
indicates the footprint of CD4. Green indicates the surface thought to be involved in chemokine receptor
binding. The base of the V3 loop is shown in magenta. B. Conserved gp120 neutralization epitopes. C. The
antigenic faces of core gp120 are shown. The non-neutralizing face (red) encompasses most of the inner
domain and N- and C-terminal regions interacting with gp41. This region is thought to be largely buried on
the assembled trimer complex and interacts with non-neutralizing antibodies. The silent face (yellow)
consists of heavily glycosylated regions on the outer domain and is poorly immunogenic. The neutralizing
face (green) extends over both domains and the bridging sheet, as well as the V2 and V3 variable loops (not
shown). This surface interacts with neutralizing antibodies.
The amino acid sequence of gp120 reveals alternating variable (V1-V5) and
conserved regions (C1-C5) (102). The variable regions V1-V4 are anchored at their bases
with disulfide bonds and mask the CD4- and coreceptor binding sites. The atomic
structure of a core gp120 deleted of variable loops V1, V2, and V3 as well as C-and N-
terminal regions in complex with the receptor CD4 and the Fab fragment of the CD4-
induced (CD4i) antibody 17b has been solved (54) (Fig. 2). The gp120 envelope
glycoprotein is structurally organized into an inner and outer domain, linked by a
bridging sheet minidomain. The inner domain is probably facing the axis of the trimeric
complex and contributes most of the contacts with gp41 at the C-and N-terminal regions.
The outer domain is heavily glycosylated and is thought to face away from the trimer
axis. Four antiparallel beta sheets form the bridging sheet. The CD4 binding site is
situated at the interface of the three domains and is relatively well conserved among viral
strains. All three domains also contribute to coreceptor binding, with the V3 loop and the
base of the V1/V2 stemloop structure providing additional contacts (81, 82).
The infection process is initiated by binding of the gp120 envelope glycoprotein
A B C
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to the cellular receptor CD4. This binding event presumably displaces the variable loop
regions V1 and V2 on the gp120 envelope glycoprotein and exposes the coreceptor
binding site, allowing for subsequent binding to the cellular coreceptor, typically the
chemokine receptor CXCR4 or CCR5. These interactions trigger further conformational
changes that allow for the formation of a six-helix bundle formed by two potential alpha-
helical regions, N36 and C34 in the gp41 ectodomain, with three C34 helices packing
into the hydrophobic grooves of a trimeric N36 coiled coil. Formation of this six-helix
bundle is proposed to bring the viral and cellular membranes into close proximity and
allow the insertion of the gp41 fusion peptide into the host cell membrane (25, 53, 115).
Antigenically, the surface of the gp120 core can be organized into three different
faces as defined by antibody binding (121) (Fig. 2). Conserved regions that are accessible
to antibodies or neutralizing ligands comprise the receptor- and coreceptor binding sites
and form the neutralizing face. The heavily glycosylated outer domain is virtually
invisible to the host immune system and is termed the silent face. The non-neutralizing
face is oriented towards the trimer axis, is not accessible to antibodies on the functional
trimer, and elicits only nonneutralizing antibodies.
1.4 Antibodies in HIV-1 infection
Vaccine-induced protection from many viral infections is based solely on the
elicitation of neutralizing antibodies. It is becoming increasingly clear that for the
prevention of HIV-1 infection, antibodies are also likely to be a critical component of a
vaccine-elicited immune response. The level of circulating neutralizing antibodies
correlated with protection from viral challenge in several animal models (12, 17). Passive
immunization with neutralizing antibodies has also been demonstrated to protect from the
establishment of viral infection in primates when administered to the host prior to
exposure with HIV-1 (5, 58, 61). Some HIV-1-infected individuals remain asymptomatic
for long periods of time and largely contain viral replication. In some cases, these long-
term nonprogressors exhibit high titers of broadly neutralizing antibodies that may
contribute to the favourable outcome of infection. The envelope glycoproteins are the
major targets for neutralizing antibodies in vivo. However, the elicitation of antibodies
that broadly neutralize HIV-1 has proven to be exceptionally difficult. The identification
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of only four broadly and potently neutralizing envelope glycoprotein-directed antibodies
to date from extensive screens of human and rodent antibodies illustrates the elusiveness
of this class of antibodies.
During HIV-1 infection, antibodies directed against the viral envelope
glycoproteins are readily elicited. In most infected individuals, two classes of neutralizing
antibodies emerge, strain-restricted and broadly neutralizing antibodies. The strain-
restricted antibodies are generally directed towards the second variable (V2) or third
variable loop (V3) of gp120 and appear early during infection (84, 92). These antibodies
neutralize only a limited number of viral isolates. Only after the initial phase of high
viremiae, when the infection has already been firmly established, do more broadly
neutralizing antibodies appear (103). These are directed to conformational epitopes, some
of which, the CD4 binding site antibodies (CD4BS), recognize the discontinuous CD4
binding site (78, 86, 111). Another group of antibodies that neutralize T-cell line adapted
(TCLA) isolates and a subset of primary isolates recognize CD4 induced (CD4i)
epitopes. These antibodies bind near the gp120 bridging sheet and interfere with gp120-
chemokine receptor interaction (110, 119).
One phenomenon of antibody neutralization that has misled the focus of research
for years is the greater neutralization sensitivity of viral isolates that have been
extensively passaged in vitro in immortalized T-cell lines compared to primary, clinical
isolates (31, 44, 60, 61, 66, 71, 117, 128). Passage in cell lines selects for viruses using
the CXCR4 coreceptor, such as the molecular clones HXBc2, IIIB, and MN. These
TCLA viruses can be neutralized by a wide range of antibodies. Viruses directly isolated
from patients, such as the molecular clones SF162, BaL, ADA, 89.6, JR-CSF, JR-FL, and
YU2, preferentially use the CCR5 coreceptor or both CXCR4 and CCR5 coreceptors.
Neutralization of primary isolates generally requires much greater concentrations of
neutralizing antibodies. This difference in neutralization resistance can most likely be
attributed to the antibody-mediated immune selection pressure on primary isolate viruses.
It appears that primary viruses, regardless of their choice of coreceptor, are more resistant
to neutralization than TCLA viruses.
To date, only four monoclonal antibodies that broadly and potently neutralize
HIV-1 primary isolates have been identified. All of these antibodies have unique
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properties and despite intensive study, no general scheme of neutralization of HIV-1 has
emerged. The CD4 binding site antibody IgG1b12 was identified from a phage-displayed
IgG Fab library obtained from the bone marrow of a long-term nonprogressor with
exceptionally high titers of serum neutralizing antibodies (21, 113). It binds the CD4
binding site and neutralizes a wide range of primary isolate viruses at nanomolar
concentrations. The atomic structure of this antibody reveals that it binds to the CD4
binding site similarly to CD4, extending a long, finger-like complementarity-determining
region 3 (CDR3) into the recessed cavity of the CD4 binding site (95). The second
broadly neutralizing gp120-directed antibody, 2G12, binds a carbohydrate moiety on the
outer face of gp120 and is a rare example of a carbohydrate-reactive gp120 antibody
(112). The gp41-binding antibodies 4E10 (129) and 2F5 (69) bind in close proximity on
the C-terminal ectodomain of gp41. The epitope of the 2F5 antibody is thought to be
linear, comprising the amino acid sequence ELDKWA, however, to date this antibody
could not be elicited by peptides containing the 2F5 epitope or any other immunogen.
1.5 T-helper cells, B-cells, and T-helper epitopes
Functional activation of the cellular and the humoral arm of the immune system
requires interaction with activated CD4+ T-helper cells (1, 51). At the same time, CD4+
T-helper cells are the major target for HIV-1 infection. In the course of AIDS, CD4+ T-
helper cells specific for HIV-1 are preferentially infected and depleted. This loss of
specific anti-HIV-1 CD4+ T-helper cells has been suggested to be a major factor in the
eventual failure of the host immune system to control the virus (34, 88).
The generation of mature antibody responses requires the interaction of B-cells
with activated CD4+ T-helper cells. Upon specific recognition of an antigen by the B-cell
receptor, the antigen is internalized and proteolytically degraded into peptide fragments
in the lysosomal compartment. Particular peptides, the T-helper epitopes, bind to the
major histocompatibility complex class II (MHC class II) and are presented on the
surface of the cell. The complex of MHC class II and T-helper epitope is then recognized
by a specific T-cell receptor (TCR) on the surface of a CD4+ T-helper cell. This
interaction and a complex series of costimulatory signals lead to the activation of the B-
cell (1, 51).
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Most large proteins possess one or more contiguous stretches of amino acids that
can function as T-helper epitopes (90). Sequence comparison of helper epitopes naturally
presented by MHC class II and structural analysis of MHC and MHC-peptide complexes
suggest key anchor residues necessary for MHC class II binding and TCR engagement
(16, 50, 89, 90). Although each MHC allele is characterized by a number of unique
polymorphic residues along the peptide-binding cleft that limit the number of potential
peptide ligands, peptides that are able to bind promiscuously to a number of different
MHC alleles have been described (23, 72, 99). This observation gave rise to the concept
of "universal helper-epitopes", peptides that can serve as T-helper epitopes for a number
of different MHC class II alleles. One such universal T-helper epitope consists of key
residues necessary for the binding to MHC class II and TCR on a polyalanine backbone.
This peptide (amino acid sequence AKFVAAWTLKAAA) was shown to bind ten out of
ten tested HLA-DR molecules and was hence termed pan-DR-helper epitope (PADRE).
The PADRE epitope was also shown to bind to certain mouse MHC class II alleles, in
particular I-Ab expressed by C57BL/6 mice (2).
1.6 Immunogenicity of the envelope glycoproteins
Most envelope glycoprotein-based immunogens tested so far are based on
monomeric gp120. The antibody responses obtained in these studies generally did not
neutralize primary HIV-1 isolates. (9, 11, 12, 30, 61, 118) The poor ability of gp120 to
elicit neutralizing antibodies is also reflected in the binding characteristics of neutralizing
and nonneutralizing antibodies. Neutralization has been found to correlate with binding
of antibodies to the mature envelope glycoprotein complex. No such correlation could be
found with monomeric gp120 (41, 83, 97).
Attempts to generate mimics of the trimeric envelope glycoprotein complex to
better elicit neutralizing antibodies have been frustrated by the lability of these
complexes. A number of different strategies have been pursued to stabilize the trimeric
complex as soluble gp140 constructs. The deletion of the proteolytic cleavage site
between gp120 and gp41 prevents shedding of noncovalently bound gp120 subunits from
the complex and is common to most gp140 ectodomain constructs. The insertion of
cysteine residues at specific locations on the alpha helical gp41 regions that mediate
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formation of the trimeric coiled coil have been used to stabilize the trimeric organization
of the envelope glycoprotein complex (37). Heterologous trimerization domains such as
the bacterial transcription factor GCN4 or the bacteriophage trimerization domain fibritin
have also been employed to stabilize the trimeric complex (122-124). Intersubunit
disulfide bonds between gp41 and gp120 have been inserted in order to stabilize the
cleaved, fully mature trimeric complex (14). The immunogenic properties of these
ectodomain constructs have been disappointing, perhaps because of their heterogeneity
(35). Only one of these constructs, a gp140-GCN4 construct derived from the primary
isolate YU2, has been shown to elicit neutralizing antibodies better than monomeric
gp120 (125). Mice immunized with these constructs generated antibodies that showed
significant neutralization of the homologous primary isolate YU2, heterologous
neutralization of the primary isolate ADA and the TCLA isolate HXBc2, but little
neutralization of other primary isolates. This may be seen as a proof of principle that
suggests better immunogenicity of trimeric constructs compared to monomeric gp120.
And yet, these molecules may not fully resemble the relevant trimeric envelope
glycoprotein complex. It is conceivable that the extensive changes that need to be
introduced in these molecules to stabilize the trimer may force the envelope glycoprotein
in conformations they would not naturally assume. Many lines of indirect evidence
suggest that the best envelope glycoprotein-based immunogen is going to be one that
most closely mimics the native envelope glycoprotein complex as it is found on the viral
surface. Broadly neutralizing antibodies are elicited in HIV-infected individuals, and a
good correlation between neutralization and binding of these antibodies to the functional
oligomeric envelope glycoprotein complex has been established (75, 83, 97). The best
protection from homologous and heterologous SIV challenge that could be achieved to
date was observed in a primate model after immunization with live attenuated virus (91).
Since inactivated virus in the case of HIV-1 may never be a safe immunogen (4,
6), the generation of virus-like particles (VLP) has been explored as a means of
preserving the native envelope glycoprotein structure in its natural lipid environment
(126, 127). These VLP, however, have been difficult to generate with envelope
glycoprotein quantities large enough to elicit sufficient titers of antibodies.
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1.7 Viral immune escape mechanisms
As a result of HIV-1 infection, a vigorous immune response occurs. Despite this
immune response, the general slow progression to AIDS ensues. The immune system
keeps the infection in check for many years until the virus eventually gains the upper
hand. Both cellular and humoral effector mechanisms exert considerable immune
pressure on the virus. The effect of the humoral response in particular is highlighted by
the difference in neutralization sensitivity that can be observed between TCLA isolates
and primary isolates (41, 65, 101). Viruses grown without antibody pressure in tissue
culture become more neutralization sensitive. During chronic infection, however, HIV-1
and the host’s immune system co-evolve for many years, during which the immune
system selects for ever more neutralization-resistant viruses, particularly resistant to
autologous antibodies.
Many escape mechanisms from antibody-mediated neutralization have been
described. Maybe most importantly, the exceptionally high genetic variability of HIV-1
allows the virus to escape from antibody recognition by mutation of antibody epitopes
and necessitates the constant adaptation of the antibody response to mutated generations
of progeny virus. Only antibodies elicited by structures that are limited in their ability to
mutate by functional constraints, such as the receptor binding sites, can potentially
neutralize different viral strains. However, large regions of the envelope glycoprotein, the
exposed variable loops V1 and V2, sterically block access to the receptor binding sites
while themselves eliciting mostly strain-restricted antibodies (121).
Moreover, large surfaces of gp120 are covered by carbohydrate moities, with
about half of the gp120 molecular weight being contributed by carbohydrates (Fig. 3).
Since these carbohydrates are synthesized by the host glycosyltransferase system, they
are considered "self" determinants by the host's immune system. Thus, the glycosylation
renders the underlying foreign protein determinants of gp120 invisible to the immune
system. The protective effect that even one single carbohydrate moiety can have is
highlighted in the case of a gp120 mutant that deletes the glycosylation site at amino acid
301. Deletion of this single glycosylation site renders a number of primary viral isolates
sensitive to neutralization by many antibodies that cannot neutralize the wild-type virus
even at high concentrations (57).
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FIG. 3. Model of oligomeric core gp120 (modified from Kwong et al., 2000). Depicted is a Cα worm
presentation of core gp120 (brown), the two membrane-distal domains of CD4 (yellow), and the gp120
carbohydrate cores (blue) as viewed from the target cell membrane. The carbohydrate cores shown
represent about half of the high-mannose and complex N-linked glycan moieties. The long, finger-like
structure extending counter-clockwise at the center of the trimer represents the V1,2 stem. The variable
loops V1,2 and V3 are not shown.
The complex organization of gp41 and gp120 as trimers of heterodimers itself has
important implications for immune diversion. It has been suggested that in vivo,
disassembled envelope glycoprotein or viral debris may be the predominant immunogen
(73). The interaction of gp41 and gp120 is noncovalent, thought to be labile, and allows
gp120 to shed from the functional complex. Upon disassembly of envelope glycoprotein
complexes, many surfaces that are occluded on the functional spike such as the
gp41/gp120 interface and areas on gp120 buried along the trimer axis are presented to the
immune system (Fig. 3). Both gp120 and gp41 may also change conformation upon
dissociation. As a consequence, many antibodies elicited in vivo are raised against these
decoy epitopes and do not bind the functional envelope glycoprotein complex.
Introduction                                                                                                                        12
Thermodynamic analysis of the interaction of gp120 with its receptor CD4
revealed highly unusual thermodynamics of this binding reaction (70). The changes in
enthalpy and entropy of this reaction greatly exceeds that of other protein/protein
interactions. The binding of CD4 to gp120 is characterized by an extraordinarily
favourable binding enthalpy of –63kcal/mol. This change reflects a large number of
bonding interactions during complex formation. The compensatory high entropy of this
reaction of ~52kcal/mol is suggestive of large conformational rearrangements in gp120
upon CD4 binding. Since similar results have been obtained with deglycosylated core
gp120 and fully glycosylated full-length gp120, these structural rearrangements are likely
to occur at the interface of the inner and outer domain and the bridging sheet. These data
have been interpreted to mean that monomeric gp120 in its free state is a very flexible
molecule, possibly sampling many conformations. Only upon ligand binding does gp120
assume a fixed conformation. One implication of this flexibility of free gp120 for
immunogenicity is that it may present a multitude of different conformations to the
immune system, most of which may be irrelevant for virus neutralization.
Mutations in viral proteins that lead to loss of recognition by CD8+ cytotoxic T
lymphocytes have been documented and shown to allow for viral immune escape (15, 45,
76, 79). It is conceivable that viral proteins that lack potential T-helper lymphocyte
epitopes for recognition by CD4+ T-helper cells will also be selected for in an infected
individual. Such escape mutants have been documented in the case of lymphocytic
choriomeningitis virus. Adoptive transfer of CD4+ T-helper cells from mice transgenic in
the T-cell receptor for the immunodominant MHC class II-restricted LCMV epitope
GP61-80 into C57BL/6 mice persistently infected with LCMV selected for virus mutants
that failed to be recognized by CD4+ T-helper cells (27). A similar mechanism has not yet
been documented for HIV-1.
1.8 Scope of this thesis
The HIV-1 envelope glycoproteins are poor immunogens. HIV-1 has evolved a
plethora of immune escape mechanisms to evade host immune surveillance. Most likely,
we are only at the beginning of understanding the complexities of immune escape that
need to be adressed and dismantled to generate better immunogens that elicit broadly
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neutralizing antibodies. It appears that the envelope glycoproteins are protected from
antibody neutralization by many layers of protection at virtually every level of immune
effector mechanisms.
1. The generation of better mimics of the functional native envelope glycoprotein
complex as it is found on the viral surface is a promising approach to limit the number of
irrelevant epitopes that are presented to the immune system by, for example, immunogens
based on monomeric envelope glycoprotein. A novel envelope glycoprotein complex
formulation containing native, trimeric envelope glycoprotein complexes embedded in a
lipid membrane, solid-phase proteoliposomes (PLs), have been generated, characterized,
and tested for immunogenicity in mice and rabbits.
2. A great wealth of information has been drawn from the four broadly neutralizing
antibodies that have been identified to date. The identification of additional neutralizing
antibodies would greatly aid our understanding of neutralization mechanisms and viral
immune escape, and may help in the identification of novel targets for vaccine design. To
this end, proteoliposomes were used to screen phage-displayed Fab and scFv libraries for
novel neutralizing antibodies.
3. Escape from T-helper cell recognition has been documented in a transgenic model for
LCMV as a viral immune escape mechanism (27). For HIV-1, such a mechanism has not
yet been described. Based on a comparison of the immunogenicity of envelope
glycoprotein core proteins derived from TCLA- and primary isolates, escape from
recognition by T-helper cells is suggested as yet another immune escape mechanism of
HIV-1.
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2 Materials and Methods
2.1 Envelope glycoprotein constructs
2.1.1 Envelope glycoprotein constructs used for the generation of proteoliposomes
The envelope glycoprotein constructs were derived from the primary R5 HIV-1
isolates YU2, JR-FL, and 89.6 and the X4, TCLA-adapted isolate HXBc2. The coding
sequences for the YU2 and 89.6 envelope glycoproteins were obtained from the
pSVIIIenv YU2 and pSVIIIenv 89.6 expression plasmid (106). The JR-FL envelope
glycoprotein coding sequence, which contains a CD5 heterologous leader sequence in
place of the normal JR-FL leader, was obtained from the AIDS repository and subcloned
into the pcDNA 3.1(-) (Invitrogen) expression plasmid. The HXBc2 construct was
codon-optimized for mammalian expression using overlapping primers and PCR and
subcloned into pcDNA3.1(+) (Invitrogen). A sequence coding for the heterologous CD5
signal sequence was subcloned to replace the endogenous HXBc2 leader sequence. For
all constructs, a cytoplasmic tail truncation was generated by introduction of a stop codon
in place of the codon for amino acid 712 (704 for JR-FL) and the sequence coding for the
C9-tag TETSQVAPA was added according to the QuikChange (Stratagene) protocol
immediately before the stop codon. To create covalently linked gp120-gp41
glycoproteins, the proteolytic cleavage site between gp120 and gp41 was disrupted by
replacing the arginines 508 and 511 with serines by QuikChange site-directed
mutagensis. These modifications resulted in constructs encoding cleavage-deficient
gp160∆CT envelope glycoproteins that were subsequently used to generate the
proteoliposomes. Amino acid residue numbers are designated according to the prototypic
HXBc2 sequence. The introduction of the desired mutations was confirmed by
sequencing.
2.1.2 Core gp120 envelope glycoproteins
The envelope glycoprotein constructs were derived from the TCLA HIV-1 isolate
HXBc2 and the primary isolates YU2 and JR-FL. The coding sequences of the envelope
glycoproteins were derived from the pSVIIIenv HXBc2, YU2, and JR-FL expression
plasmids containing deletions of the V1 and V2 variable loops as previously described
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(120). Briefly, the V1/V2 coding region was deleted from amino acids 128 to 194
(HXBc2 numbering) and replaced with a Gly-Ala-Gly sequence. Subcloning of
sequences encoding these V3-containing core glycoproteins into the insect expression
vector pMT (SmithKline Beecham Pharmaceuticals) containing the inducible
metallothionein promoter was performed as follows. The gp120 core coding regions were
amplified by PCR to remove the N- and C-terminal sequences (∆82 and ∆492) and to
append a 5' BamHI and a 3' XbaI site. The PCR products were digested with BamHI and
XbaI. The pMT expression plasmid was digested with BglII and NheI to obtain
compatible overhangs. The insert was then ligated into the pMT expression plasmid. For
the generation of gp120 core constructs containing 5' and 3' PADRE sequences, the
PADRE sequences (amino acid sequence: AKFVAAWTLKAAA) (2) as well as BamHI
and XbaI sites were appended by PCR to the core-coding sequence in the pMT
expression plasmid. The PCR products were digested with BamHI and XbaI and inserted
into the pMT vector cut with BglII and NheI. The presence of the PADRE sequences was
confirmed by DNA sequencing.
2.2 Expression of envelope glycoprotein constructs
2.2.1 Expression of gp160∆CT
Plasmids expressing the gp160∆CT glycoproteins (2µg DNA per 100mm dish of
cells) were transfected into 293T cells using Effectene reagent (QIAGEN) following the
manufacturer's protocol. For the expression of YU2 and 89.6 envelope glycoproteins, the
HIV-1 Tat expressor plasmid pSVTat (0.5µg) was cotransfected with the plasmids
expressing the gp160∆CT glycoproteins. Thirty-six to fourty-eight hours after
transfection, cells expressing the envelope glycoproteins were harvested with PBS
containing 5 mM EDTA.
2.2.2 Core gp120 envelope glycoprotein
To establish Drosophila S2 cell lines that stably express core gp120, Drosophila
S2 cells were transfected by the CaPO4 method (93) using a 20:1 ratio of the gp120
construct-expressing pMT vector and the hygromycin B resistance-conferring plasmid
pchygro. Following transfection, S2 cells were washed and maintained in MRD4 medium
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(SmithKline Becham Pharmaceuticals) supplemented with 5% FCS and 0.1% pluronic F-
68 (Sigma) at 25oC. After 48 hours, hygromycin B (Boehringer Mannheim) was added to
a final concentration of 300µg/ml. When growth was observed in the cultures 3-4 weeks
after transfection, the cultures were expanded and incubated in shaking flasks at 25oC.
The cells were expanded and induced to produce recombinant envelope glycoprotein by
pelleting the cells at 300xg and resuspending them in serum-free induction medium
(MRD4 containing 750µM CuSO4 and 0.1% pluronic F-68). The cells were then
incubated with shaking at 25oC for five to seven days. The cell supernatant was collected
and filtered through a 0.45µm filter system (Corning). The supernatant was passed over
an F105 antibody affinity column prepared from F105 antibody covalently linked to
Protein-A Sepharose (Amersham Bioscience). The column was washed with 10 column
volumes of PBS/0.5M NaCl, followed by 10 column volumes of PBS. Bound protein was
eluted with 5 ml of 100mM glycine-HCl pH2.3 and the eluate was neutralized by adding
2M Tris base. The eluate was then concentrated using a Centriprep YM-30 concentrator
(Millipore). The protein concentration of the preparation was determined photometrically
by determining the absorption at 280nm using extinction coefficients determined for each
gp120 construct according to the primary amino acid sequence.
2.3 Deglycosylation of envelope glycoproteins
For the enzymatic deglycosylation of Drosophila-produced gp120, the proteins
(0.5mg/ml) were treated with 0.1 unit/ml Endoglycosidase D and 0.25 units/ml
Endoglycosidase H (Roche) in 0.5M NaCl, 100mM sodium acetate buffer, pH5.7 for 10
hours at 37oC. The deglycosylation of gp120 was confirmed by SDS-PAGE as reduction
in molecular weight relative to WT gp120 protein.
2.4 Generation of proteoliposomes
Paramagnetic proteoliposomes containing the HIV-1 envelope glycoprotein were
created according to methods established for solubilization and membrane reconstitution
of the CCR5 chemokine receptor (64). Tosyl-activated Dynabeads (Dynal) were
conjugated with the 1D4 antibody (National Cell Culture Center) according to the
manufacturer’s protocol. The 1D4 murine antibody recognizes the C9 epitope tag and
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was used to capture the envelope glycoproteins on the Dynal beads. For the
characterization of proteoliposomes, beads with a diameter of 4.5µm (M-450) were used,
for immunizations and phage display, beads with a diameter of 2.8µm (M-280) were
used.
Cells expressing gp160∆CT envelope glycoproteins were harvested in PBS
containing 5mM EDTA, washed in PBS and lysed in 5ml solubilization buffer (100mM
(NH4)2SO4, 20mM Tris-HCl (pH7.5), 1% (w/v) Cymal-5 and one tablet of Complete
Protease Inhibitor Mixture [Boehringer Mannheim] per 50ml) at 4oC for 30 min on a
rocking platform. For the preparation of 4x108 M-450 or 2x109 M-280 proteoliposomes,
the amount of gp160∆CT envelope glycoprotein produced by transient transfection of six
150 mm tissue culture dishes of 293T cells was found to be sufficient for saturation of the
beads. Cell debris was pelleted by centrifugation for 30min at 14,000xg. The cleared
lysate was incubated with 1D4-conjugated Dynal beads for 16h at 4oC on a rocking
platform. After recovery of the beads, they were extensively washed in solubilization
buffer.
Lipids were obtained as chloroform solutions from Avanti Polar Lipids. The
following lipids were used: 1-Palmitoyl-2-Oleoyl-sn-Glycero-3-Phosphocholine (POPC),
1-Palmitoyl-2-Oleoyl-sn-Glycero-3-Phosphoethanolamine (POPE) and
Dimyristoylphosphatidic acid (DMPA) and Cholesterol at molar concentrations
45:25:20:10. The lipid mixture was dried in a 2-ml polyethylene tube under vacuum until
all of the solvent was removed. PBS was added to the tube and a liposomal solution was
obtained by ultrasonication for 5min in an ice bath using an Ultrasonic Processor (Heat
Systems Inc.). Liposomal solutions of the head group-modified synthetic lipids 1,2-
dioleyl-sn-glycero-3-phosphoethanolamine-n-(biotinyl) (Biotinyl-DOPE) and
dioleoylphosphoethanolamine-lissamine rhodamine B (Rho-DOPE), at a final
concentration of 1mg/ml, were prepared separately using the same protocol. For the
formation of the lipid membrane, beads coated with gp160∆CT glycoprotein were
incubated for 15min at RT with 1ml solubilization buffer containing 2mg of lipid
mixture, and, if fluorescence labeling or biotinylation was desired, with 1% of Rho-
DOPE or biotin-PE. The detergent was slowly removed by dialysis for 24h at 4°C against
PBS, using a 10kDa molecular weight cutoff dialysis membrane (Slide-A-Lyzer 10 K
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[Pierce]). The excess of unbound lipid and residual detergent was removed on a magnetic
separator in one washing step with PBS. Proteoliposomes were stored in PBS with 0.1%
BSA/0.1% Na2N3 at 4°C for up to three months.
2.5 SDS-PAGE
2.5.1 gp160∆CT eluted from proteoliposomes
Approximately 5x107 Proteoliposomes and control beads devoid of gp160∆CT
were incubated at 100°C in reducing SDS sample buffer for 5min, separated on a
7.5%SDS-polyacrylamide gel and stained with Coomassie blue.
To determine that gp120 was present in the protein peaks eluted during molecular
exlusion chromatography, samples from each peak were incubated for 5min at 100°C in
sample buffer containing 2% BME and separated on a 7.5% SDS-polyacrylamide gel. To
confirm that oligomeric forms of envelope glycoproteins could be detected in the high
molecular weight peaks, the fractions were diluted in sample buffer lacking BME and
separated on a 3-8% SDS-polyacrylamide gel. A sample from the peak consistent with a
trimer was also analyzed in the presence of 2% BME. 
2.5.2 Core gp120 envelope glycoproteins
For the detection of core gp120, 2µg of purified core gp120 was incubated at
100°C in reducing SDS sample buffer for 5min, subsequently separated on a 12% SDS-
PAGE gel and stained with Coomassie blue.
2.6 Molecular exclusion chromatography
The gp160∆CT glycoproteins captured onto Dynal beads were eluted from the
beads for molecular exclusion chromatography under non-denaturing conditions as
follows. The beads were incubated in 0.5M MgCl2, 1% CHAPS, and 0.2mM C9 peptide
(peptide sequence: TETSQVAPA) at 37oC for 30min. Approximately 5µg of eluted
gp160∆CT glycoproteins were loaded onto a Superdex 200 column (Amersham
Pharmacia Biotech) in a 200µl volume. The column was then eluted with PBS containing
1% CHAPS at a rate of 0.5ml/min for 40min. The eluted protein was detected by
measuring the optical density at 280nm (OD280) using a Varian ProStar System (Varian
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Analytical Instruments). Fractions of the flow-through were collected at 2 minute
intervals using a Varian Dynamax Fraction Collector. The fractions were further analyzed
by reducing and non-reducing SDS-PAGE and Western blotting using a polyclonal anti-
gp120 rabbit serum for detection of HIV-1 envelope glycoproteins. A mixture of high
molecular weight protein markers (Amersham Pharmacia Biotech) was eluted under
identical conditions to calibrate the column.
2.7 Western blot
For the analysis of fractions eluted by molecular exclusion, Western blotting was
performed after SDS-PAGE under either non-reducing or reducing conditions. Proteins
were electrophoretically transferred onto a 0.45 µm Hybond-C extra membrane
(Amersham). The gp160∆CT glycoproteins present in each column fraction were then
detected by anti-gp120 rabbit serum at a dilution of 1:2000 and anti-rabbit IgG-
horseradish peroxidase (HRP) (Sigma) at a dilution of 1:5000.
2.8 Flow cytometric analysis
For the comparison of antibody binding to either cleavage-defective or cleavage-
competent gp160∆CT envelope glycoproteins, 293T cells were transfected with plasmids
expressing the two envelope glycoprotein variants. Approximately 106 cells per sample
were harvested with PBS containing 5mM EDTA and washed once in FACS buffer
(PBS, 2% FCS, 0.02% Na2N3). The cells were incubated for 1 hour at RT with the
indicated amounts of antibodies in a volume of 100µl. After two washing steps in FACS
buffer, the cells were incubated for 30min with a R-Phycoerythrin (PE)-conjugated
F(ab’)2 goat anti-human antibody (Jackson Immuno Research Laboratories, Inc., West
Grove, PA) at a dilution of 1:200, washed twice and analyzed with a FACScan flow
cytometer and CellQuest software (Beckton Dickinson). For FACS analysis of
proteoliposomes, staining was performed as described above. Staining for membrane
integrity of the proteoliposomes was performed using a PE-conjugated goat anti-mouse
IgG (Boehringer Mannheim) or Avidin-FITC (Sigma) at a dilution of 1:200. The
following ligands were used for staining of the envelope glycoproteins: soluble CD4, the
potently neutralizing CD4BS antibody IgG1b12 (kindly provided by Dennis Burton), the
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F105 CD4BS antibody (kindly provided by Marshal Posner), the strain-restricted
neutralizing V3 loop antibody 39F, the non-neutralizing C1/C4 antibody A32, the non-
neutralizing C1/C5 antibody C11, the CD4-induced 17b antibody (all kindly provided by
James Robinson) and the broadly neutralizing gp41 antibody 2F5 (kindly provided by
Hermann Katinger).
2.9 Animals, immunization, and serum preparation
2.9.1 Immunization with proteoliposomes
2.9.1.1 Mice
To determine the immunogenicity of M-450 Dynal beads and proteoliposomes,
and to determine adjuvant requirements for immunization with proteoliposomes, groups
of four BALB/c mice were inoculated as follows. For the immunization of group A,
0.5x107 of M-450 conjugated with the 1D4 antibody was inoculated in 200µl MPL+TDM
adjuvant (Sigma) emulsion subcutaneously. For group B, 2µg of affinity-purified YU2
gp120 was inoculated in 200µl MPL+TDM adjuvant emulsion subcutaneously.
Proteoliposomes containing gp160∆CT envelope glycoprotein (0.5x107 of M-450
proteoliposomes in 200µl volume) were either resuspended in 200µl of MPL+TDM
adjuvant (group D) or the adjuvant solution was administered to the site of inoculation
one day prior to inoculation with proteoliposomes (group C) to limit the exposure of
proteoliposomes to the detergent-containing adjuvant. The inoculation was repeated three
times (two times for group D) in four week intervals. Eyebleeding was performed seven
days after inoculations. The blood was collected, incubated at 4oC O/N to allow for clot
formation, and serum was cleared for 10min at 14,000rpm in an Eppendorf microtube
centrifuge. The cleared serum was stored at 4oC.
2.9.1.2 Rabbits
Groups of five New Zealand White rabbits were inoculated intradermally with
1ml of MPL+TDM+CWS adjuvant emulsion (Sigma) containing the respective antigen.
The amounts of YU2 gp120 and YU2gp140-GCN4 envelope glycoprotein were adjusted
to the same molar quantity of the gp120 moiety. Thus, each rabbit received 18.9µg of
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YU2 gp120 and 25µg of YU2gp140-GCN4. Animals inoculated with proteoliposomes
received 1ml MPL+TDM+CWS adjuvant emulsion containing approximately 1.8x109 M-
280 proteoliposomes. Inoculations were administered 2, 6, 10, and 22 weeks after the
initial inoculation. Ear bleeding was performed thirteen days after the second and seven
days after the fourth inoculation and fifth inoculation (Table 1). The blood was incubated
O/N at 4oC in a Vacutainer SST Gel Clot Activator (Becton Dickinson) and spun for
30min at 2000xg at 4oC. The cleared serum was collected and incubated for 30min at
55oC to inactivate complement. The sera were then stored at -20oC.
2.9.2 Immunization with core gp120 envelope glycoproteins
2.9.2.1 Mice
Female, four week old mice were purchased from Taconic. Groups of six
C57BL/6 and BALB/c mice were inoculated subcutaneously with 20µg of gp120
resuspended in 200µl of MPL+TDM adjuvant (Sigma). The inoculation was repeated
four times in four week intervals. Eyebleeding and serum preparation was performed as
described above.
2.9.2.2 Rabbits
For the immunization of rabbits, 20µg of envelope glycoprotein was resuspended
in 1 ml of MPL+TDM+CWS adjuvant (Sigma). Groups of five New Zealand White
rabbits were inoculated intradermally with 1ml of the emulsified antigen. Inoculations
were administered 4, 8, and 12 weeks after the initial inoculation. Earbleeding was
performed thirteen days after each inoculation except the first. The blood samples were
incubated overnight at 4oC in a Vacutainer SST Gel Clot Activator (Becton Dickinson)
and cleared for 30min at 2000xg at 4oC. The cleared serum was stored at -20oC.
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2.10 ELISA
2.10.1 Detection of anti-gp120 reactivity in serum
To determine the anti-gp120 reactivity in the serum raised from immunizations
with proteoliposomes or core-gp120, 100ng of affinity-purified mammalian-expressed
YU2 gp120 (for the sera raised against proteoliposomes) or, for the sera raised against
core-gp120, affinity-purified Drosophila-expressed core or full length gp120 derived
from the HXBc2 or YU2 isolate was adsorbed onto each well of a high-protein-binding
microwell plate (Corning) in PBS over night at 4oC. After blocking the plates in 100µl
blocking buffer (PBS/2% dry milk/5% FCS), serial serum dilutions in ELISA blocking
buffer were incubated in each well for 1h at RT. After three washes with PBS/0.2%
Tween-20, mouse serum binding to gp120 was detected as follows. A 1:2000 dilution of
anti-mouse-IgG-biotin antibody (Sigma) in washing buffer was added for one hour,
followed after three washes by an incubation with horseradish peroxidase (HRP)-
conjugated Streptavidin (Sigma) at a 1:4000 dilution for 30min. For the analysis of rabbit
sera, a secondary Anti-Rabbit-IgG-HRP antibody (Sigma) was added in washing buffer at
a 1:2000 dilution for one hour at RT. For the detection of IgM titers in rabbit serum, an
anti-rabbit-IgM-HRP antibody (Sigma) was used at a 1:2000 dilution. Following three
washes, the ELISAs were developed with 100µl TMB Peroxidase substrate (KPL). The
reaction was stopped by adding 100µl 1M HCl to each well. After 5min, the optical
density at 450nm was read on a microplate reader (Molecular Devices). Endpoint titers
were defined as last reciprocal serum dilution at which the absorption at 450nm was
greater than two-fold over the signal detected with preimmune serum.
2.10.2 Detection of gp120- and gp41-binding of scFv and Fab antibodies
For the detection of gp120-binding of Fab and scFv antibodies by ELISA,
Microplate wells (Corning) were coated overnight at 4°C with 50µl of PBS containing
100ng/well of the following antigens: Affinity-purified YU2 gp120, affinity-purified IIIB
gp41, and, for the detection of unspecific binding, BSA (New England Biolabs). The
wells were washed twice with PBS/0.02% Tween-20 and blocked with PBS/3% BSA for
1h at 37°C. After a single wash, 20µl of Fab- or scFv-containing supernatant and 20µl
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PBS/1% BSA/0.02% Tween-20 was added to the wells and allowed to incubate at 37°C
for 1h. For the detection of purified scFv and Fab antibodies, the desired antibody
concentration was added in 100µl PBS/0.02% Tween-20. The wells were washed four
times. For Fab detection, goat anti-human IgG F(ab')2 alkaline phosphatase (Pierce)
diluted 1:500 in PBS containing 1% BSA was added, and the plate was incubated for
40min at RT. The wells were washed five times and developed by adding 50µl of alkaline
phosphatase substrate (one tablet of disodium p-nitrophenyl phosphate [Sigma] to 5ml of
alkaline phosphatase staining buffer [pH 9.8]). After 30min, the optical density at 405nm
was read on a microplate reader (Molecular Devices). For the detection of scFv, mouse
anti-HIS IgG (Santa Cruz Biotechnology) was added at a 1:500 dilution in PBS/0.02%
Tween-20 and incubated for 40min at room temperature. After three washes, anti-mouse-
IgG- HRP (Sigma) diluted 1:2000 in PBS/0.02% Tween-20 was added and incubated for
30min at RT. After three washes, the wells were developed and detected as described
above.
2.10.3 Competition ELISA with sCD4 and D-mannose
Microplate wells (Corning) were coated overnight at 4°C with 50µl of PBS
containing 100ng/well of Drosophila-expressed YU2 gp120. For sCD4 competition
ELISA, the wells were incubated with sCD4 in 50µl PBS for 1h at RT. The antibodies
were added to the wells at a concentration of 20µg/ml in 50µl PBS/0.02% Tween-20, thus
obtaining a final antibody concentration of 10µg/ml. The wells were washed and
developed as described above for Fabs.
For D-mannose competition ELISA, D-mannose (Sigma) was added to the wells
in 50µl PBS/0.02% Tween-20. 50µl serum at a dilution of 1:250 in PBS/0.02% Tween-20
or 50µl antibodies at a concentration of 5µg/ml in PBS/0.02% Tween-20 were added to
obtain a final serum dilution of 1:500 and a final antibody concentration of 2.5µg/ml. The
wells were washed and developed as described above for rabbit serum.
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2.11 Phage display
2.11.1 Panning of a naïve human phage-displayed scFv antibody library
The paramagnetic proteoliposomes were used to screen a naïve human single-
chain antibody phage display library generated from a healthy uninfected donor. Before
each round of selection, proteoliposomes were incubated with PBS/2% non-fat dry milk
for 30min at RT. The proteoliposomes were adsorbed onto a magnet (Dynal) and
incubated with the phage-displayed scFv library stock (approximately 1012 phage) for
30min at RT. After binding of the phage, the proteoliposomes were washed three times
for 10min with PBS/2% non-fat dry milk after the first round of selection, four times for
10min with PBS after the second round of selection, and four times 15min after the fourth
round of selection. For the first two rounds of selection, 4x107 YU2 M-450
proteoliposomes were used. The following two rounds of selection were performed with
2x107 proteoliposomes. The phage were eluted after each round by incubation with 100µl
0.1M HCL pH2.2 for 10min on a rocking platform. The eluted phage were neutralized
with 1M Tris to pH7. After each round of panning, a counterselection step with 4x107
beads conjugated with 1D4 antibody but devoid of gp160 was performed. The phage
were infected into E.coli TG-1 bacteria and rescued by infection with M13 helper phage
(Stratagene). After the fourth round of selection, phage produced by individual bacterial
clones were tested for binding to gp120. Individual colonies were inoculated into a 96-
well plate and induced to produce phage particles into the bacterial supernatant by
infection with helper phage. The bacterial supernatants were tested for their ability to
bind to YU2 gp120 by ELISA. Clones positive for gp120-binding were subjected to DNA
sequencing to identify unique scFv antibodies.
2.11.2 Panning of biased human phage-displayed scFv and Fab antibody libraries
Six libraries generated from the bone marrow of HIV-1-infected asymptomatic
donors (biased libraries) were panned with proteoliposomes as antigen. The library FDA-
2 was panned as a Fab and a scFv library, the libraries DS, DL, DA, and MT were panned
as Fab libraries only. For the panning of the FDA-2 Fab library, two separate libraries
were prepared initially, one containing kappa light chains and one containing lambda
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light chains. Libraries of either kappa or lambda light-chain variable-region fragments
were panned separately for one round with each antigen and then combined. The DS, DL,
DA and MT libraries were panned separately for one round of panning and then pooled
for the three subsequent pannings. All libraries were subjected to four rounds of affinity
selection against the respective antigen.
For affinity selections of the biased libraries, M-280 proteoliposomes were
prepared as described. Per round of panning, 30-50µl proteoliposomes were blocked with
4% non-fat dry milk for 1h at 37°C. After adsorption onto a magnet, the proteoliposomes
were incubated with the phage library (1011-1012 phage diluted in 50µl of PBS/1% BSA).
The proteoliposomes were incubated with the library for 1h at 37 °C on a rocking
platform. After adsorption of the proteoliposomes onto a magnet, the proteoliposomes
were washed twice with PBS alone, and once in PBS/1% BSA for different times
according to the stringency desired in the particular experiment. The proteoliposomes
were adsorped onto a magnet and the phage were eluted using 100µl 0.1M HCL pH2.2
with 1mg/ml BSA for 10min on a rocking platform. The eluted phage were then
counterscreened for 30 min at RT on a rocking platform to absorb unspecific reactivities.
The eluted phage were incubated with the following counterscreening reagents: 50µl of
1D4-coupled M-280 Dynabeads (pannings A, B, F, G, H, J, and K), 2.5µg YU2 gp120
coated onto the well of an ELISA plate (panning C), CCR5 Proteoliposomes (panning D),
and YU2gp140-GCN4 complexed with sCD4 on proteoliposomes containing CCR5
(panning E). After counterscreening, the phage were infected into E.coli XL-blue and
rescued with M13 helper phage.
From the enriched Fab phage pools after four rounds of selection, the pComb3
vector containing the Fab genes was obtained and engineered to secrete soluble Fab by
polyclonal restriction digest of the library with NotI and NheI (New England Biolabs),
thus deleting the bacteriophage coat protein geneIII. After religation of the vector, the
library was transformed into E.coli XL1-blue (Stratagene). From the enriched scFv phage
pools, the pComb3 vector was obtained and transformed into nonsuppressor E.coli strain
TOP10 (Stratagene).
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2.12 ScFv and Fab production
For small-scale production of Fab- and scFv-containing cell lysates for the
screening of individual colonies for gp120- or gp41-binding, individual colonies of XL-
1blue (Fab) and TOP10 (scFv) were inoculated into 10ml superbroth medium (SB [for 1
liter, 10g of 3-(N-morpholino)propanesulfonic acid (MOPS), 30g of tryptone, and 2g of
yeast extract (pH 7)] containing 20mM MgCl2, tetracycline (10µg/ml), and carbenicillin
(50µg/ml) and incubated for 8h at 37°C. After adding 1mM IPTG to the cultures, they
were incubated O/N at 37°C. The cells were pelleted, resuspended in 1ml PBS and lysed
by three cycles of freezing in a dry-ice/ethanol bath and thawing. Cell debris was pelleted
by centrifugation at 13,000xg for 10min and the cleared Fab- or scFv-containing
supernatant was used for ELISA.
For large-scale preparations, a single colony of each Fab-expressing (scFv-
expressing) clone of XL-1blue (TOP10) was used to inoculate an overnight culture of
10ml containing 20mM MgCl2, tetracycline (10µg/ml), and carbenicillin (50µg/ml). The
overnight culture was then used to inoculate 8 liters of SB medium containing 20mM
MgCl2, tetracycline (10µg/ml), and carbenicillin (50µg/ml). The cultures were incubated
at 37°C with shaking at 250rpm until an optical density at 600nm of 0.8 was reached,
after which time 1mM IPTG was added to each culture. The cultures were then incubated
for a further 16h at 30°C. The cultures were pelleted by centrifugation at 8,000rpm for
15min in a Sorvall SLA-3000 rotor at 4°C, and the pellets were resuspended in 30ml of
PBS containing 0.3 µM phenylmethylsulfonyl fluoride (PMSF). The bacteria were lysed
by sonication (Misonix sonicator, 1/2-in. horn) four times at 50% cycle time (power 7 for
20s). The bacterial lysate was centrifuged at 17,000rpm in a Sorvall SS-34 rotor for
35min at 4°C. The supernatant was filtered (pore size, 0.8µm and then 0.2µm) and loaded
onto a 5ml Protein G-Sepharose column for the purification of Fabs and a Ni-NTA
column for the purification of scFv. The Fab was eluted with 0.2M glycine-HCl (pH2.2),
neutralized with 2M Tris base (pH9). The scFv were eluted in 200mM Imidazole. Fab
and scFv eluate was concentrated with a Centriprep YM-30 (Fab) and YM-10 (scFv)
concentrator (Millipore) and dialyzed against PBS (pH 7).
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2.13 HIV-1 single-round neutralization assay
The HIV-1 neutralizing activity of serum or antibodies was determined using a
single-round virus entry assay, measuring infection by FACS detection of pseudotyped
GFP reporter viruses or detection of infectious molecular clones by intracellular p24-Ag
staining.
The intracellular p24-Ag neutralization assays were performed in 96-well culture
plates. For each antibody or serum dilution, two wells were set up and combined to
produce enough cells for precise quantitation by flow cytometry. 40µl of virus stock were
incubated with the desired amount of purified antibodies in 10µl volume or 10µl of serum
to obtain a serum dilution of 1:5. Approximately 20,000 TCID50 (determined by a 14-day
titration assay) of HIV-1 was added to each well. After incubation for 30min at 37°C,
20µl of PBMC (1.5x105 cells) was added to each well. PBMC were maintained in IL-2
culture medium containing 1µM indinavir, and the cells were fed on day 1 with 150µl of
IL-2 culture medium containing indinavir. Since there were 150,000 PBMC per well, the
resulting MOI was approximately 0.1.
PBMC were harvested for intracellular p24-Ag staining on day two. For
intracellular p24-Ag staining, cells were transferred to V-bottomed plates and washed
once in PBS containing 1% FCS. Cells were fixed and permeabilized using the
Cytofix/Cytoperm Kit (BD-PharMingen). Permeabilized cells were washed twice in V-
bottomed plates using the wash buffer provided by the manufacturer and resuspended for
20min at 4°C with 50 µl of a 1:160 dilution of a phycoerythrin (PE)-conjugated mouse
anti-p24 Mab (KC57-RD1; Beckman Coulter, Inc.), or a mouse IgG1 isotypic control
antibody. After two additional washes, HIV-1- or mock-infected PBMC were analyzed
with a FACSCalibur flow cytometer (Becton Dickinson), and data analysis was
performed with FlowJo software (Tree Star). For the measurement of infection with
pseudotyped GFP reporter viruses, infected cells were washed once in FACS buffer and
directly detected. Live cells initially gated by forward and side scatter were analyzed for
intracellular expression of p24-Ag or GFP. The number of p24-Ag-positive cells or GFP-
positive cells was determined using a bivariate plot of fluorescence versus forward
scatter; the gate was set on mock-infected cells. To enumerate infected PBMC, cells were
washed, fixed and permeabilized, and stained with the KC57 anti-p24 antibody as
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described above. After forward and side scatter gating, at least 50,000 events were
counted. Final quantitation of p24-Ag-positive cells was done by subtraction of
background events in mock-infected PBMC (usually less than 10 positives per 50,000
events). The percent neutralization was defined as reduction in the number of p24-Ag-
positive cells and GFP-positive cells, respectively, compared with the number in control
wells with individual prebleed serum or no antibody, respectively.
IC50, IC80, and IC90 values were determined as follows. Antibody dose-response
curves were fit with a nonlinear function and the concentration of antibody required for
50, 80, or 90% reduction (IC50, IC80, IC90, respectively) of infection was calculated by a
least-squares regression analysis.
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3 Results
3.1 Generation and characterization of proteoliposomes
3.1.1 Creation of gp160∆CT proteoliposomes
293T cells transiently expressing the HIV-1 YU2, JR-FL, 89.6 or HXBc2
gp160∆CT glycoproteins, which contain an alteration of the gp120-gp41 cleavage site
and deletion of the gp41 cytoplasmic tail, were lysed in buffer containing Cymal-5
detergent. The gp160∆CT glycoproteins were then captured onto Dynal beads conjugated
to the 1D4 antibody, which recognizes a C9 peptide tag affixed to the gp160∆CT C-
terminus. Following addition of membrane lipids and dialysis of the Cymal-5 detergent,
an artificial lipid bilayer is formed around the bead surface (Fig. 4). Thus, pure, properly
oriented HIV-1 envelope glycoproteins, embedded in a natural membrane environment,
were incorporated into an easily manipulable solid support.
3.1.2 Analysis of proteoliposome protein composition
The gp160∆CT proteoliposomes were boiled in sample buffer and analyzed by
reducing SDS-PAGE to determine their protein composition. As a positive control, cell
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lysates containing transiently expressed gp160∆CT glycoproteins were
immunoprecipitated with the F105 anti-gp120 antibody and protein A-Sepharose and
analyzed in parallel. Proteoliposomes lacking the gp160∆CT glycoproteins were treated
similarly and served as a negative control. As seen in Fig. 5A, a band migrating at a
position similar to the gp160∆CT glycoprotein positive control band (lane 1) was
observed among the proteins released from the gp160∆CT proteoliposomes (lane 2). No
such band was observed in this molecular weight range in the gp160∆CT glycoprotein-
deficient proteoliposome control sample (lane 3). Apart from a 50kD band corresponding
to the 1D4 antibody heavy chain, a light chain band not retained on the gel, and the
gp160∆CT band, only minor impurities were detected in the gp160∆CT proteoliposomes.
The total amount of gp160∆CT glycoproteins captured onto 5x107 proteoliposomes was
estimated to be 1-2 µg, as determined by the purified recombinant gp160∆CT
glycoprotein control of known concentration.
FIG. 5. Protein composition of proteoliposomes. (A) SDS-PAGE gel of gp160∆CT glycoproteins eluted
from 5x107 proteoliposomes, stained with Coomassie blue. Lane 1 shows 1µg of affinity-purified gp160,
lane 2 shows protein eluted from gp160∆CT PLs and lane 3 shows protein eluted from beads conjugated
with the 1D4 antibody. (B) FACS analysis of proteoliposomes stained with the IgG1 b12 antibody (peak 2)
and HIV-1 patient serum (peak 3), compared to anti-human FITC secondary antibody alone (peak 1).
To examine the exposure of the HIV-1 envelope glycoproteins on the
proteoliposome surface, the gp160∆CT proteoliposomes were stained with the IgG1b12
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anti-gp120 antibody and a mixture of sera from HIV-1-infected individuals and analyzed
by fluorescence-activated cell sorting (FACS). The IgG1b12 antibody recognizes a
conformation-dependent gp120 epitope near the CD4 binding site. The forward scatter
versus sideward scatter plot showed mostly single proteoliposomes. Doubles and other
multiples of proteoliposomes were generally observed to be less than 20% of the total
events (data not shown). A gate was created to analyze only single proteoliposomes and
was used for all further FACS analyses. The narrow distribution of the fluorescence
intensity associated with each FACS peak following antibody staining suggests that the
gp160∆CT proteoliposomes have nearly uniform protein content (Fig. 5B).
3.1.3 Characterization of the size of the gp160∆CT proteoliposome envelope
glycoproteins
The gp160∆CT glycoproteins were eluted from the reconstituted proteoliposomes
under non-denaturing conditions by incubation with 0.2 mM C9 peptide in the presence
of 1% CHAPS detergent and 0.5M NaCl. The eluted envelope glycoproteins were
analyzed by size-exclusion chromatography on a Superdex 200 column equilibrated in
PBS/1%CHAPS buffer. The chromatogram for the HIV-1 JR-FL gp160∆CT envelope
glycoproteins is shown in Fig. 6A. Parallel studies using the YU2 gp160∆CT
glycoproteins yielded a similar profile (data not shown). The fractions of the resolved JR-
FL glycoproteins were collected and analyzed by SDS-PAGE and Western blotting (Fig.
6B).
The column was calibrated with molecular weight standards, allowing the
apparent molecular size of the major peak to be approximated as 580kD. As the gp120
glycoprotein monomer was resolved by size-exclusion chromatography with an apparent
molecular weight of 180kD (data not shown and (122)), a mass of 580kD is consistent
with that of a trimeric gp160∆CT envelope glycoprotein complex. The fastest migrating
protein peak was detected just after the void volume and apparently consists of
gp160∆CT glycoprotein aggregates as determined by its migration pattern in the column
and by the Western blot results (Fig. 6C). This aggregate peak has previously been 
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observed in molecular exclusion chromatography of soluble GCN4-stablized gp140
trimers (122). Most of the gp160∆CT glycoprotein eluted in fractions 3 and 4, with
fraction 3 corresponding to the mass of 580kD. When all of the gel filtration fractions
were subjected to non-reducing SDS-PAGE (with pretreatment in gel loading buffer at
37oC) followed by Western blotting, fractions 3 and 4 contained trimeric envelope
glycoproteins, which were found to separate into trimers, dimers and monomers. The
highest level of gel-stable trimeric envelope glycoprotein was detected in fraction 3 (Fig.
6C). Most of the glycoproteins migrating with molecular weight corresponding to trimers
in this fraction could be almost completely reduced to a monomeric gp160∆CT band by
treatment with 2% β-mercaptoethanol (BME) and boiling, although bands migrating in a
manner consistent with trimers and dimers could still be observed (Fig. 6C).
3.1.4 Characterization of the proteoliposome membrane
The formation of the lipid membrane was examined by FACS analysis and
fluorescent microscopy. According to our model, the murine 1D4 capture antibody would
be expected to be partially occluded by a reconstituted lipid membrane. Thereby, binding 
FIG. 7. FACS analysis of the reconstituted proteoliposome membrane. (A) Occlusion of the 1D4 antibody
by lipid membrane reconstitution. gp160∆CT proteoliposomes with (peak 2) and without (peak 3) a
reconstituted membrane were probed with anti-mouse Ig-PE antibody. Peak 1 shows staining with the same
antibody of non-conjugated beads. (B) proteoliposomes with a reconstituted membrane containing 1%
biotinylated lipid (peak 2) and beads without a reconstituted membrane (peak 1) were probed with Avidin-
FITC.
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of anti-mouse IgG antibody should be impaired on proteoliposomes when compared to
beads without a membrane. A more than 3-fold decrease of anti-mouse-PE signal could
be observed on proteoliposomes containing a reconstituted lipid membrane versus beads
without lipid reconstitution (Fig. 7, left panel, peak 2 compared to peak 3), indicating the
presence of at least a partial lipid membrane.
The presence of the lipid membrane was also examined by FACS analysis after
reconstitution of the membrane with biotinylated lipid at 1% (w/w) of total lipids. The
proteoliposomes were stained with avidin-FITC and showed more than a 20-fold higher
signal on fully reconstituted proteoliposomes compared to gp160∆CT glycoprotein-
containing beads without lipid reconstitution (Fig. 7, right panel). The presence of a lipid
bilayer was then confirmed by visualizing the incorporation of rhodamine-conjugated
lipid (rhodamine-DOPE) into the proteoliposome membrane by fluorescent microscopy
(Fig. 8). Bright fluorescence could be observed in the rhodamine-labelled
proteoliposomes (B) compared to negligible background fluorescent emission with
untreated beads (A).
FIG. 8. Fluorescent microscopic image. (A) unconjugated beads and (B) proteoliposomes reconstituted
with a membrane containing 1% DOPE-Rhodamine.
3.1.5 Antigenic characterization of the gp160∆CT proteoliposomes
To confirm the conformational integrity of the gp160∆CT glycoproteins on the
surface of the proteoliposomes, binding of a panel of conformationally-sensitive ligands
A B
1% Rhodamine-DOPEAuto fluorescence
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to gp160∆CT glycoproteins on proteoliposomes was compared with binding to
gp160∆CT glycoproteins expressed on the surface of transiently-expressing cells.
FIG. 9. Binding of a panel of anti-gp120 antibodies and soluble CD4 (sCD4) to YU2 gp160∆CT
glycoprotein expressed on 293T cells compared to YU2 gp160∆CT glycoprotein on proteoliposomes. Cells
(open circles) and proteoliposomes (closed squares) were incubated with increasing amounts of the
indicated human antibodies, followed by detection with anti-human IgG-PE antibody. For detection of
sCD4 binding to the glycoproteins, the rabbit anti-CD4 antibody T45 and anti-rabbit IgG FITC were used.
Following staining, samples were analyzed by FACS. The binding of ligands to gp160∆CT PLs was plotted
as % normalized mean fluorescent intensity (MFI) at serially-diluted antibody concentrations. The %
normalized MFI values were calculated according to the formula: [MFI-
MFI(background)]x100/MFI(saturation)-MFI(background). Error bars indicate the range of values obtained
for duplicate samples.
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The antibodies were selected to probe several faces of the HIV-1 envelope
glycoproteins, including the neutralization-relevant epitopes overlapping the CD4
binding site (CD4BS). The potently neutralizing CD4BS antibody IgG1b12, the less
potent neutralizing CD4BS-antibody F105, and soluble CD4 (sCD4) were used to
confirm the correct native conformation of the CD4BS. In addition, gp160∆CT
proteoliposomes were probed with the strain-restricted neutralizing V3-loop antibody
39F, and the non-neutralizing antibodies A32 and C11. The binding characteristics of all
antibodies to the gp160∆CT proteoliposomes compared to gp160∆CT glycoproteins
expressed on the cell surface were virtually indistinguishable (Fig. 9). The only
difference in binding profiles was observed for soluble CD4 (sCD4). For the
Proteoliposomes, sCD4 displayed an almost tenfold higher affinity than it did for
gp160∆CT glycoproteins expressed on cell surfaces. This affinity difference may be a
consequence of better exposure of gp160∆CT glycoproteins on the proteoliposomes due
to the lack of the cellular glycocalix and cellular protein components. The observed
affinities calculated for the antibodies were in the low nanomolar range, consistent with
previously reported values (77, 83). For example, the affinity of the antibody IgGb12, as
determined by the concentration necessary to achieve half-maximal binding, was
calculated to be 6 nM. The affinity of the non-neutralizing C11 antibody was at least 10-
fold lower than that of the neutralizing IgG1b12 antibody. This underestimates the
affinity difference between the two antibodies because saturation binding was not
achieved with the C11 antibody.
3.1.6 2F5 antibody binding to gp160∆CT proteoliposomes
The epitope of the broadly neutralizing antibody 2F5, ELDKWAS, is situated
proximal to the viral membrane in the gp41 ectodomain. To determine the influence of
the reconstituted membrane on this important neutralizing determinant, we used the 2F5
antibody to probe proteoliposomes reconstituted with a membrane and proteoliposomes
coated with gp160∆CT glycoprotein but devoid of a membrane. Since sequence variation
in the HIV-1 YU2 strain alters 2F5 antibody recognition, proteoliposomes with
gp160∆CT glycoproteins derived from the primary isolate JR-FL and the T-cell line
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adapted isolate HXBc2 were examined. The 2F5 antibody bound to HXBc2 gp160∆CT
glycoprotein proteoliposomes with a reconstituted membrane with approximately a ten-
fold higher affinity than it did to HXBc2 gp160∆CT glycoprotein on beads without a
membrane (Fig. 10, upper right panel). The same could be observed with JR-FL
proteoliposomes, although the effect was less pronounced (Fig. 10, upper left panel). To
show the specificity of the enhanced 2F5 binding observed in the presence of the
reconstituted membrane, binding of the gp120-specific antibodies F105 and 2G12 to
gp160∆CT proteoliposomes with and without a membrane was examined. No affinity
difference could be detected using these antibodies (Fig. 10 lower panel).
FIG. 10. Upper panel: Binding of the gp41 antibody 2F5 to gp160∆CT from JR-FL (left) and HXBc2
(right) on beads without a membrane (open squares) and fully reconstituted proteoliposomes (closed
squares). Proteoliposomes and beads were probed with increasing concentrations of 2F5 antibody and anti-
human IgG-PE antibody and analyzed by FACS. The MFI was plotted as % maximal MFI at the given
antibody concentration. Lower panel: Binding of the antibodies 2G12 (left) and F105 (right) to the PLs
(closed squares) and beads (open squares) was performed as described for 2F5 binding above.
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3.1.7 CD4 induction of the 17b epitope
One functional conformational change characteristic of native gp120 is the
induction of the 17b antibody epitope by CD4 (106). To test whether the gp160∆CT
glycoproteins on proteoliposomes exhibit this property of gp120 expressed on the cell
surface, gp160∆CT glycoprotein proteoliposomes and 293T cells expressing cleavage-
competent envelope glycoproteins were preincubated with sCD4 prior to binding of the
17b antibody. 17b binding was detected by staining with a PE-conjugated anti-human
IgG antibody followed by FACS analysis. The binding of the 17b antibody was increased
by 63% after preincubation with sCD4 on cleavage-competent gp160∆CT glycoprotein
expressed on cells compared to a 46% increase on gp160∆CT Proteoliposomes (Fig. 11).
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increased 8-fold over full-length constructs containing the intact gp160 cytoplasmic tail
(data not shown).
FIG. 12. Effect of proteolytic cleavage of HIV-1 envelope glycoprotein on ligand binding. Cleavage-
competent YU2 gp160∆CT glycoprotein (closed squares) and cleavage-defective YU2 gp160∆CT
glycoprotein (open circles) was expressed on 293T cells. Cells were incubated with increasing amounts of
the indicated ligands followed by detection with anti-human IgG-PE. The anti-CD4 polyclonal rabbit
antibody T45 and anti-rabbit IgG-FITC was used for the detection of sCD4 binding. Normalized MFI was
calculated as described for Fig. 9.
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It is possible that the deletion of the cleavage site might distort envelope
glycoprotein conformation and result in a conformation not representative of functional,
cleaved envelope glycoprotein. To assess the effects of the cleavage site deletion, the
binding properties of a panel of conformationally-sensitive ligands to cleavage-defective
and cleavage-competent gp160∆CT glycoproteins expressed on the cell surface were
analyzed. FACS analysis was performed by staining the gp160∆CT expressed on 293T
cells with increasing concentrations of ligands. No significant affinity difference was
observed between cleavage-competent gp160∆CT glycoproteins and cleavage-defective
envelope glycoproteins for any of the ligands tested (Fig. 12). However, one notable
difference in the binding profiles was observed. The binding profile of sCD4 on cells
expressing cleavage-competent gp160∆CT glycoproteins had a biphasic shape. As sCD4
is known to induce shedding of gp120 from envelope glycoprotein complexes (67), CD4
binding to the cleavage-competent gp160∆CT glycoprotein may induce shedding or other
conformational changes that result in a biphasic binding profile.
To confirm the processing of the cleavage-competent envelope glycoproteins,
293T cells were transfected with cleavage-competent and –defective envelope
glycoprotein constructs. Proteins expressed on the cell surface were iodinated by
lactoperoxidase. After detergent lysis and precipitation with the F105 antibody, iodinated
proteins were analyzed by SDS-PAGE. The ratio of unprocessed gp160∆CT precursor
proteins to cleaved gp120 was determined to be approximately 1:1 (data not shown).
3.2 Immunogenicity of proteoliposomes
3.2.1 Immunogenicity of proteoliposomes in mice
To initially test the immunogenic properties of M-450 Dynabeads and
proteoliposomes and to determine adjuvant requirements for immunization, M-450
Dynabeads conjugated with 1D4 antibody but devoid of YU2 gp160∆CT envelope
glycoprotein and proteoliposomes containing YU2 gp160∆CT envelope glycoprotein
were generated and inoculated into mice as described in Materials and Methods. As
control, one group of mice was inoculated with affinity-purified monomeric YU2 gp120
(Fig. 13). The serum was tested for anti-gp120 activity by ELISA and endpoint titers
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were determined as the last reciprocal serum dilution at which an at least two-fold higher
signal over background signal detected with preimmune serum could be observed.
The animals inoculated with M-450 Dynabeads conjugated with the 1D4 antibody
did not generate detectable anti-gp120 antibody titers, suggesting that Dynabeads
conjugated with the mouse 1D4 antibody do not elicit antibodies crossreactive with
gp120 (Fig. 13). The serum of animals inoculated with YU2 gp120 envelope glycoprotein
raised an anti-gp120 directed response with endpoint titers of >700,000 after three
inoculations. One group of animals was inoculated with MPL+TDM adjuvant the day
prior to inoculation with proteoliposomes at the site of injection to limit the exposure of
proteoliposomes to the detergent-containing adjuvant. The animals in this group
displayed much lower enpoint titers of >1250. The animals inoculated with
proteoliposomes in MPL+TDM adjuvant raised anti-gp120 endpoint titers of >30,000
after two inoculations. The enpoint titers after three inoculations were not determined for
this group. The effect of the adjuvant on the proteoliposome membrane was determined
by incubation of proteoliposomes with either PBS or adjuvant and the integrity of the
membrane was monitored at different timepoints by FACS detection of biotinylated
lipids incorporated into the membrane (data not shown). A slight loss of Streptavidin
signal could be observed over time. However, exposure of the proteoliposomes to
adjuvant did not cause greater loss of membrane signal than did incubation with PBS.
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FIG. 13. ELISA of mouse serum.
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gp120 activity at the indicated serum
dilutions after three inoculations (after
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adjuvant group).
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Higher antibody titers could be raised with proteoliposomes coadministered with
adjuvant rather than inoculation of adjuvant and proteoliposomes on different days. Since
no detrimental effect of the adjuvant on the proteoliposome membrane could be detected,
proteoliposomes were coadministered with adjuvant in all subsequent proteoliposome
inoculations.
These data demonstrated the general feasability of immunizations with these
novel reagents. No toxicity could be observed in the animals inoculated with Dynabeads,
and anti-gp120 antibody titers similar to those raised against soluble gp120 could be
elicited by proteoliposomes. The amount of mouse serum obtained by these experiments
was not sufficient to reliably and reproducibly test for neutralizing activity against a
panel of viruses.
3.2.2 Immunogenicity of proteoliposomes in rabbits
The immunogenicity of proteoliposomes in different immunization protocols was
determined and compared to the immunogenicity of the YU2 gp120 envelope
glycoprotein and YU2 gp140-GCN4 envelope glycoprotein. Many reports have shown
that monomeric gp120 does not elicit broadly neutralizing antibodies and only after
aggressive immunization elicits antibodies capable of neutralizing homologous strains.
The YU2 gp140-GCN4 envelope glycoprotein used in this study has previously been
shown to elicit neutralizing antibodies with limited breadth in mice (125). These
envelope glycoprotein immunogens represent to date the most effective envelope-based
immunogens for the elicitation of broadly neutralizing antibodies. Here we tested whether
an envelope glycoprotein formulation that possibly recapitulates the trimeric envelope
glycoprotein complex more faithfully (proteoliposomes) would better elicit broadly
neutralizing antibodies in rabbits.
Slight variations in the amounts of envelope glycoproteins incorporated into
proteoliposomes could be detected among the envelope glycoproteins derived from
different viral isolates used for proteoliposome preparation. The least efficient
incorporation of envelope glycoprotein constructs was observed with the JR-FL-derived
construct. The amounts of envelope glycoproteins on proteoliposomes inoculated were
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estimated to be approximately 5µg/dose by gel analysis (data not shown). The presence
of the lipid membrane around the proteoliposomes was confirmed before each
inoculation by FACS analysis detecting biotinylated lipids incorporated into the
membrane. Proteoliposomes containing the envelope glycoproteins from the molecular
clones HXBc2, 89.6, JR-FL and YU2 were generated. A summary of the immunization
protocol is given in Table 1.
Table 1. Schematic diagram of rabbit immunization. The immunogens and times of inoculation and
bleeding are given. Horizontal arrows indicate repeated administration of the same immunogen.
The immunization protocol consisted of a priming inoculation followed by four
boosts at two, six, ten, and twenty-two weeks after priming (Table 1). Sera were collected
seven days after boosts two, three, and four and assessed for gp120-reactivity and HIV-1
neutralizing reactivity. Reactivity of sera against YU2 gp120 was assessed by ELISA. All
groups except group E generated solid anti-gp120 antibody titers with endpoint titers
>62,500 (except animal 19, see ELISA data in Table 2). Differences in serum reactivity
could be observed between different groups. The highest serum reactivity was detected in
sera from rabbits immunized with YU2 gp140-GCN4 envelope glycoprotein, and the
lowest reactivity was detected in sera from rabbits immunized sequentially with the four 
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Table 2. HIV-1 single-round in vitro neutralization assay using rabbit serum at a 1:5 dilution against a
panel of viral isolates. Serum was collected after four inoculations. Numbers indicate % neutralization,
which was determined as follows. The effect of individual preimmune serum on infection was determined
relative to infection without serum and is given in lower case, italicised numbers. The percent
neutralization of immune serum was determined using the reactivity of individual preimmune sera as
baseline neutralization and is given in bold numbers. Asterisks indicate neutralization observed against
unusually high enhancement of infection with preimmune serum. Endpoint ELISA titers were defined as
last reciprocal serum dilution at which a signal of greater than two-fold over the signal of preimmune serum
was detected. The symbols represent the following endpoint titers. (+++) 62,500 (++) 12,500 (+) 2500 (+/-)
2500-500 (-) less than 500. ND: Not determined.
Endpoint viral isolate
Immunogen Animal ELISA HXBc2 SF162 89.6 BaL ADA YU2
9.8 11.1 -35.3 -42.4 -46.4 -4.5
+++ 36.5 51.8 35.8 22.0 10.1 -3.3
32.9 36.9 -1.5 9.3 -42.4 29.5
+++ 43.6 9.9 26.1 -5.2 -6.0 -51.6
40.2 59.5 35.3 18.1 -23.6 13.6
++ 36.7 34.7 -6.8 -3.2 -6.0 -35.5
45.1 22.8 10.3 -3.3 -44.7 4.5
++ 28.9 36.4 1.6 -3.0 -0.8 -14.3
52.4 20.5 17.6 9.8 -41.3 15.9
+++ 12.8 55.0 -1.8 -2.3 11.3 -32.4
45.1 27.5 8.8 2.5 -51.0 9.1
+++ 64.4 72.2 35.4 31.6 14.4 71.3
47.6 27.5 23.5 12.9 -28.7 23.9
+++ 81.9 79.7 13.4 24.0 11.1 90.1
28.0 33.0 -5.9 8.7 -44.7 6.8
+++ 83.1 85.1 31.9 9.7 6.3 64.6
46.3 50.2 19.1 10.3 -31.6 5.7
++ 47.7 28.2 -9.1 -19.8 -8.3 -26.5
36.6 43.1 17.6 3.5 -24.1 19.3
++ 48.1 16.5 12.5 8.1 -13.8 31.0
45.1 60.3 23.5 14.0 -29.3 30.7
++ 26.7 5.9 0.0 12.7 5.3 -50.8
35.4 40.0 16.2 17.1 -25.9 19.3
+ 35.8 14.3 -7.0 -35.9 -3.2 -43.7
54.9 49.4 27.9 12.9 -29.9 26.1
+++ 56.8 44.8 -4.1 18.0 4.4 44.6
48.8 58.8 22.0 6.1 -33.3 29.5
+++ 47.6 64.4 20.7 30.6 6.0 96.1
46.3 40.8 7.3 21.3 -23.6 28.4
+++ 68.2 60.7 22.2 -11.9 9.7 -31.7
46.3 43.9 30.9 19.7 -28.7 15.9
++ 38.6 75.2 -2.1 25.3 5.3 78.4
48.8 -224.7 -280.6 -54.9 -36.2 9.1
+++ 64.3 *93.5 *82.9 45.8 2.5 36.3
36.6 43.1 32.3 18.1 -28.2 1.1
++ 61.5 61.8 8.7 -14.0 2.7 8.0
36.6 42.4 13.2 4.6 -13.3 0.0
+++ 76.9 61.0 40.6 43.2 -3.5 -2.3
46.3 33.0 11.8 4.6 -34.4 ND
+ 40.9 38.5 11.7 0.5 4.7 ND
46.3 53.3 41.1 18.1 -37.9 31.8
+ 47.7 65.2 -22.5 3.8 10.0 -61.7
42.7 21.3 11.8 20.2 -34.4 3.4
- 44.7 36.7 6.7 -16.3 5.5 -40.0
37.8 43.1 17.6 12.9 -36.7 19.3
- 68.6 56.3 19.6 19.2 25.1 -62.0
35.4 44.7 7.3 10.8 -34.4 -3.4
+ 20.8 50.8 12.7 6.4 2.1 -47.3
YU2 gp140
   GCN4
YU2 gp140
   GCN4/
  YU2 PL 
HXBc2 PL/
  89.6 PL/
JR-FL PL/
  YU2 PL
YU2 PL
7
8
9
10
11
12
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
YU2 gp120
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different envelope glycoprotein proteoliposomes. The anti-gp120 reactivity of sera raised
against YU2 gp120 and YU2 proteoliposomes were similar and in between that of the
two other groups.
To assess neutralizing activity in the sera, 1:5 serum dilutions of preimmune and
immune serum obtained after four inoculations were tested in a single-round in vitro
neutralization assay (59) against the clade B molecular clones HXBc2, SF162, BAL,
89.6, ADA, and YU2 (Table 2). This panel of viruses represents a range of neutralization
phenotypes, with increasing resistance from the TCLA isolate HXBc2 to the primary
isolate YU2.
In previous experiments, preimmune rabbit serum was found to exhibit a wide
range of nonspecific activity on single-round neutralization assays ranging from
enhancement of infection to neutralization, often greater than 50% (data not shown). To
be able to assess the neutralizing reactivity in individual sera relative to the baseline
reactivity of preimmune serum in these animals, sera were tested individually and
compared to the corresponding individual preimmune sera. The neutralizing activity was
determined as a decrease in infection compared to infection observed with preimmune
serum. As observed previously, preimmune sera had a significant effect on viral
infection. Compared to data from infections in the absence of serum, enhancement of
infection as high as 50% was commonly observed (Table 2, italicised numbers). Most
preimmune sera neutralized virus by 2.3 to 60.3%, averaging around 30%. Enhancement
of infection was also frequently observed. Given this wide variation, only neutralization
greater than 50% was considered significant.
The weakest neutralizing activity was found in the YU2 gp120 group with only
two animals generating antibodies neutralizing >50% of infection with the isolate SF162,
the most neutralization-sensitive of the primary isolates tested. No homologous
neutralization of the YU2 isolate was observed in this group; in contrast, immune serum
consistently enhanced infectivity of the YU2 isolate.
The animals inoculated with YU2 gp140-GCN4 exhibited the greatest degree of
both homologous and heterologous neutralization (Table 2). Three out of four animals
significantly neutralized the isolates HXBc2, SF162, and YU2, with one of the animals
(#14) neutralizing both HXBc2 and YU2 and one animal (#15) HXBc2 and SF162 by
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more than 80%. By comparison, a high concentration (1mg/ml) of a mixture of IgG
purified from sera obtained from HIV-1-infected individuals (HIV-IG) was required in
the same experiment to neutralize infection by 96.8% and 94.2%, respectively (Table 3).
To achieve neutralization of >90% of the HXBc2 isolate, 0.5 and 5µg/ml of the potent
neutralizing monoclonal antibodies 2F5 and 2G12, respectively, were required. To
achieve >90% neutralization of SF162, 50µg/ml 2F5 were required; 2G12 did neutralize
the SF162 isolate by only 72.8% at the highest antibody concentration tested (50µg/ml)
(Table 3). No neutralization greater than 50% was observed in this group (YU2 gp140-
GCN4) of the primary isolates 89.6, BAL, and ADA.
Table 3. HIV-1 single round in vitro neutralization assay using HIV-IG and monoclonal anti-envelope
glycoprotein antibodies against a panel of viral isolates. Numbers indicate % neutralization. Data were
obtained in the same experiment as data in Table 2. (*) For the neutralization of HXBc2, ten-fold lower
concentrations of HIV-IG and monoclonal antibodies than indicated were used.
To overcome the limitations of the amount of protein that could be inoculated into
each animal in the proteoliposome format, one group of rabbits received two inoculations
of 25µg of YU2 gp140-GCN4 followed by two inoculations of YU2 proteoliposomes. In
this group, only two animals displayed neutralizing activity greater than 50% with one
and two viruses, respectively (Table 2). Rabbit 21 showed the greatest homologous
neutralization of the YU2 isolate of all rabbits with 96.1% neutralization. This
neutralizing activity, however, crossed over only to the SF162 isolate, which was
neutralized by 64.4%. Overall, the neutralizing reactivity in this group was markedly
poorer than that in the group inoculated with YU2 gp140-GCN4 alone.
In the group inoculated with YU2 proteoliposomes, all five animals displayed
neutralizing activity greater than 50% against at least two viral isolates. Animal 24 may
be the only exception in this regard, since the neutralizing activity of 82.9% and 93.5%
µg/ml
viral isolate
HXBc2* SF162 89.6 BaL ADA YU2
10000 96.8 100.2 99.6 99 97 99.5
1000 58.5 94.2 80.8 70.8 75.3 64.8
50 100 93.8 92.5 77.6 85.6 95
5 95.6 71.3 52.8 40.6 46.7 62.5
50 96.1 72.8 83.7 81.3 23.9 -1.1
5 53.7 59.5 61.7 62 8.4 1.1
HIV-IG
2F5
2G12
µg/ l
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against isolates 89.6 and SF162, respectively, are likely due to the unusual enhancing
effect detected in preimmune serum of these animals (280.6% and 224.7%). This
enhancement may artificially elevate the calculated % neutralization. Homologous
neutralization of the YU2 isolate was weaker in this group than in the animals inoculated
with YU2 gp140-GCN4. Only one animal significantly neutralized the YU2 isolate
(animal 23 with 78.4% neutralization), while other animals showed little effect or even
enhancement of infection (animals 22 and 26). Overall, the neutralization activity of sera
from this group, when achieved, was weaker than that observed in the animals inoculated
with YU2 gp140-GCN4.
The sequential inoculation with different envelope glycoprotein proteoliposomes
(group 5) was designed to focus the immune response on the conserved determinants of
the envelope glycoproteins. Here, the hypothesis was tested that antibodies directed
against the highly variable loop regions are less efficiently elicited because the respective
loops are only presented once to the immune system. The conserved regions, however,
are presented four consecutive times, allowing for B-lymphocytes recognizing these
regions to be repeatedly stimulated. This group displayed the lowest anti-gp120 titers as
determined by ELISA (Table 2). This may be a consequence of a lower envelope
glycoprotein dose in this group due to less efficient JR-FL incorporation into
proteoliposomes (data not shown). Very limited neutralizing activity was observed in this
group with all animals showing enhancement of infection with YU2 and only weak
neutralization of SF162 (animals 28, 30, 31) and HXBc2 (animal 30). The poorer
neutralization performance of these sera, however, may merely reflect the lower overall
titers of anti-gp120 antibodies present in the sera.
To assess if repeated boosting after an extended resting period of three months
increases neutralizing antibody titers, the animals were inoculated for a fifth time. No
consistent boosting effect could be observed (Table 4). The overall anti-gp120 ELISA
endpoint titers in serum after the fifth inoculation were generally equal or lower by one 5-
fold dilution than those observed after the fourth inoculation (Table 4). Only some
animals displayed better neutralizing activity after the fifth inoculation compared to the
fourth inoculation, but this better neutralizing activity was not consistently observed for
all viral isolates. Better neutralizing activity after the additional inoculation could, for
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example, be observed in serum from animal 12 against HXBc2 and 89.6. Against the
viral isolates SF162 and YU2, however, the neutralizing activity decreased (Table 4). No
consistent effect of the additional boost on the neutralizing activity in serum could be
observed.
Table 4. HIV-1 single-round in vitro neutralization assay using rabbit serum at a 1:5 dilution against a
panel of viral isolates. Numbers indicate % neutralization. Serum was collected after inoculation four (first
row) and five (second row) for each animal. Percent neutralization and endpoint ELISA titers were
calculated as described for Table 2. ND: Not determined.
Endpoint viral isolate
Immunogen Animal ELISA HXBc2 SF162 89.6 BaL ADA YU2
+++ 36.5 51.8 35.8 22.0 10.1 -3.3
++ 32.4 16.2 13.5 -17.5 13.7 -21.3
+++ 43.6 9.9 26.1 -5.2 -6.0 -51.6
+++ 21.3 39.0 -1.2 40.8 -51.8 -100.0
++ 36.7 34.7 -6.8 -3.2 -6.0 -35.5
++ -124.1 32.8 -26.9 16.6 -162.0 -150.0
++ 28.9 36.4 1.6 -3.0 -0.8 -14.3
++ 7.0 4.7 -71.9 -20.2 -31.3 -59.7
+++ 12.8 55.0 -1.8 -2.3 11.3 -32.4
++ 40.6 -31.1 -31.1 -19.1 2.0 -45.8
+++ 64.4 72.2 35.4 31.6 14.4 71.3
++ 88.3 49.7 72.7 16.9 -21.7 58.1
+++ 81.9 79.7 13.4 24.0 11.1 90.1
++ 70.9 54.8 50.3 -16.8 -30.7 77.4
+++ 83.1 85.1 31.9 9.7 6.3 64.6
+++ 94.7 95.9 35.5 20.2 -31.7 55.6
++ 47.7 28.2 -9.1 -19.8 -8.3 -26.5
++ 74.9 -16.3 -55.0 -63.3 -39.9 -53.8
++ 48.1 16.5 12.5 8.1 -13.8 31.0
+ 27.1 -2.3 -41.8 -59.1 -40.4 13.7
++ 26.7 5.9 0.0 12.7 5.3 -50.8
+ 13.6 -15.3 -89.1 -50.9 -39.0 -84.0
+ 35.8 14.3 -7.0 -35.9 -3.2 -43.7
+/- -11.2 -40.5 -161.4 -117.3 -37.8 -70.2
+++ 56.8 44.8 -4.1 18.0 4.4 44.6
++ 36.5 9.9 -7.5 -44.2 -65.4 25.5
+++ 47.6 64.4 20.7 30.6 6.0 96.1
++
+++ 68.2 60.7 22.2 -11.9 9.7 -31.7
++ 80.0 32.4 23.8 -44.5 -18.8 -60.0
++ 38.6 75.2 -2.1 25.3 5.3 78.4
+ 19 0.0 -103.7 -15.1 -52.3 52.1
+++ 64.3 *93.5 *82.9 45.8 2.5 36.3
++ 56.1 74.2 29.8 7.4 -53.8 4.0
++ 61.5 61.8 8.7 -14.0 2.7 8.0
+ 40.5 9.9 8.7 -24.9 -16.3 -22.6
+++ 76.9 61.0 40.6 43.2 -3.5 -2.3
++ 54.0 14.5 57.7 -19.7 -7.7 -57.6
+ 40.9 38.5 11.7 0.5 4.7 ND
+/- -5.1 -46.8 6.6 -57.5 -31.9 -57.6
+ 47.7 65.2 -22.5 3.8 10.0 -61.7
+/- 7.4 19.5 -88.2 -52.1 -24.1 -124.4
- 44.7 36.7 6.7 -16.3 5.5 -40.0
+/- 6.3 18.6 -91.0 -2.8 -37.5 -76.3
- 68.6 56.3 19.6 19.2 25.1 -62.0
+ 20.8 50.8 12.7 6.4 2.1 -47.3
+/- 13.6 34.0 -16.5 -49.3 -17.6 -69.5
ND
ND
YU2 gp140
   GCN4
YU2 gp140
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  YU2 PL 
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Serum from animal 24 that displayed neutralization of >80% of the isolates 89.6
and SF162 after the fourth inoculation, and unusually high enhancement of infection with
preimmune serum, showed no significant neutralization against the 89.6 isolate after the
fifth inoculation. Thus, the neutralization observed in serum from this animal after
inoculation four is most likely an experimental artefact, as it could not be detected after
the fifth inoculation. Neutralization of the SF162 isolate in serum from this animal,
however, could still be detected after the fifth inoculation (74.2% versus 93.5% after the
fourth inoculation). With preimmune serum enhancement in this experiment being 59.5%
and within the range of normal variation (data not shown), the neutralizing reactivity
against the SF162 isolate in this animal does not appear to be an experimental artefact.
Notably, the neutralization of the SF162 isolate by most sera decreased after the
additional fifth boost. In the sera raised against YU2 proteoliposomes in particular, a
decrease in neutralizing activity could be observed. This raises the possibility of variation
of the viral preparation or variation of the PBMC target cells. This, however, would not
explain the decreased ELISA titers after boost five. The neutralization of monoclonal
antibody 2F5 and HIV-IG used as internal controls in both assays against SF162,
however, were highly reproducable with a variation of neutralization of <5%.
In summary, sera from the group inoculated with YU2 gp140-GCN4 displayed
the greatest neutralizing activity. The homologous viral strain YU2 as well as HXBc2 and
SF162 were efficiently neutralized by three out of four animals. No neutralization of the
isolates ADA and BaL could be observed in any of the groups. Only one animal
inoculated with proteoliposomes displayed homologous neutralization, but neutralization
of the strains HXBc2 and SF162 was observed in four out of five animals in this group.
None of the other groups displayed notable neutralizing activity.
3.3 Proteoliposomes as antigens
3.3.1 Identification of HIV-1 envelope glycoprotein-binding antibodies from phage-
displayed antibody libraries
Seven phage-displayed antibody libraries were panned with proteoliposomes
containing envelope glycoproteins, or the chemokine
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Table 5. Summary of phage display panning experiments. The libraries panned, the antigen used, blocking
regimens and counterscreens are indicated for each experiment.
receptor CCR5 in complex with YU2 gp140-GCN4 and CD4. A scFv library generated
from healthy uninfected donors was obtained from Dr. Wayne Marasco. The FDA-2 Fab-
and scFv-libraries (8, 20), as well as the MT, DS, DL, and DA libraries (13) were
generated from the bone marrow of asymptomatic HIV-1 infected patients in the
laboratory of Dr. Dennis Burton. These libraries contain the IgG1 and IgG3 isotypes and
lambda and kappa light chains. A summary of the panning experiments is given in table
5. After four rounds of selection, Fab and scFv antibodies were produced and individual
clones were tested by ELISA for their reactivity to ovalbumin, gp41 derived from the
viral isolate IIIB, and YU2 gp120 with or without prior incubation with CD4. Clones that 
Panning Library Antigen Blocking Counterscreen
A FDA-2 Fab YU2 1D4 on M-280
B FDA-2 Fab
89.6,
JR-FL, YU2,
YU2
1D4 on M-280
C FDA-2 Fab YU2
YU2 gp120,
α-gp41
cluster II
YU2 gp120
D FDA-2 Fab
CCR5 PL-
YU2 gp140 GCN4
-CD4
X5 scFv,
α-gp41
cluster II
CCR5 PLs
E
Unbound
phage
from D
YU2
CCR5-
YU2 gp140 GCN4
-CD4
F FDA-2 Fab YU2 Fab b6 1D4 on M-280
G FDA-2 scFv YU2 Fab b6 1D4 on M-280
H FDA-2 Fab 89.6 cleavage + 1D4 on M-280
I FDA-2 scFv 89.6 cleavage + 1D4 on M-280
J DS/DL/DM YU2 1D4 on M-280
K MT YU2 1D4 on M-280
L
Naïve
scFv
library
YU2 1D4 on M-450
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Table 6. Summary of Fab- and scFv antibodies identified from phage display pannings.
tested positive with gp41 or gp120 were sequenced and compared to sequences of
antibodies that had previously been identified from the same libraries. Novel Fab or scFv
antibodies were then produced in larger amounts, purified, and tested for neutralization of
HIV-1 infection in a single-round neutralization assay.
In total, fifteen different clones binding to either gp120 or gp41 were identified in
the twelve panning experiments. A summary of the antibody clones, the panning
experiments they were obtained from, the epitopes and phenotypes as well as neutralizing
activity is given in table 6. Whereas the panning of the biased libraries FDA-2, MT, DS,
DL, and DA yielded six CD4BS antibodies, two CD4-induced antibodies, two gp41
antibodies and one gp120 binder that is not yet characterized well (pannings A-K), the
naïve library yielded four unique V3 loop-binding antibodies (panning L). Pannings E, F,
G, H, and I did not yield gp120 or gp41 binding antibodies. Only clones that exhibited
significant neutralization of HIV-1 in a preliminary neutralization assay were analyzed
further. Of the sixteen clones, four displayed significant HIV-1 neutralizing activity. The
Fab C12 was found to be a variant of the recently identified neutralizing Fab fragment,
X5, that was retrieved from the FDA-2 library with JR-FL gp120 in complex with CCR5
scFv
Fab
Clone Panning Epitope/Phenotype HIV-1 neutralization
Fbb21 A gp120/CD4-induced +
Ia3 A,B gp120/CD4BS +
Fbb4 A gp41 cluster II -
Fbb14 B gp120/CD4BS +/-
C12 A,B,C gp120/CD4-induced +++ (Moulard et al.)
D10 D CD4 ND
J5 J gp120/CD4BS + (Ditzel et al.)
J10 J gp120 ND
J2 J gp41 +/-
CG5 A gp120/CD4BS +++
CG9 A,B gp120/CD4BS +++
CG21 B gp120/CD4BS ++
1 L gp120/V3 loop ND
6 L gp120/V3 loop ND
7 L gp120/V3 loop ND
10 L gp120/V3 loop +/-
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and CD4 (68). This Fab fragment was not analyzed further. Three more antibodies with
neutralizing activity were identified from the FDA-2 Fab library, CG5, CG9, and CG21.
3.3.2 Characterization of CG5, CG9, and CG21
Sequence analysis indicates that the heavy chain complementarity determining
regions (CDR 3) af CG5, CG9, and CG21 are 15, 16, and 22 amino acids in length,
respectively. The VH genes are from the VH3 (CG5, CG9) and VH1 (CG21) gene
families. The heavy chain CDR3 sequences of CG5, CG9, and CG21 were unique, and no
significant similarities could be found in GenBank. The Fab fragments CG5, CG9, and
CG21 all have gp120-affinities in the nanomolar range as determined by ELISA (data not
shown).
FIG. 14. CD4 competition ELISA. Binding of Fabs CG5, CG9, and CG21 and of control antibodies F105,
F91 (CD4BS antibodies), A32 and 2G12 to gp120 after preincubation with increasing concentrations of
sCD4 was detected.
Initial epitope mapping of CG5, CG9, and CG21 was performed by competition
ELISA with a panel of monoclonal antibodies against different regions on the gp120
envelope glycoprotein and sCD4. CD4BS antibodies and sCD4 inhibited the binding of
the CG Fabs to gp120 (data not shown). To further analyze the effect of sCD4 on
Fab/gp120 binding by ELISA, gp120 was preincubated with sCD4 at different
concentrations and the CG Fabs or control antibodies were incubated with the
gp120/sCD4 complexes (Fig. 14). The binding of the CG Fabs to gp120 was inhibited by
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sCD4 in a dose-dependent manner. At the highest concentration of sCD4, binding of the
Fabs to gp120 was inhibited by approximately 80% (Fig. 14, left panel). As control
antibodies, the CD4BS antibodies F105 and F91 were used, as well as the 2G12 and A32
antibodies that bind a cluster of mannose moieties on the outer domain and the C1/C4
region of YU2 gp120, respectively. A similar degree of inhibition of binding to gp120 by
sCD4 was observed with the two CD4BS antibodies, whereas binding of the 2G12 and
A32 antibodies was either not affected or enhanced by increasing amounts of sCD4
(Fig.14, right panel).
3.3.3 Neutralization of in vitro HIV-1 infection by Fab CG5, CG9, and CG21
The ability of the Fab fragments CG5, CG9, and CG21 to neutralize infection of
PBMC (A3R5 cells for YU2) by a panel of HIV-1 isolates in a single-round in vitro
neutralization assay was determined and compared to that of a panel of other human
monoclonal Fab fragments of CD4 binding site antibodies. The inhibition of in vitro
infection of PBMC with a panel of HIV-1 isolates at different antibody concentrations
was determined and the concentrations at which the antibodies neutralize 50, 80, or 90%
infection (IC50, IC80, and IC90) were derived from the neutralization data. A
representative dose response curve for neutralization of the MN viral isolate is shown in
Fig. 15. The IC50, IC80, and IC90 concentrations are indicated. The Fab fragments of the
monoclonal CD4BS antibodies F105, F91, and b12 were tested side by side with CG5,
CG9, and CG21 as controls to establish a rank order of neutralizing potency (Table 7).
FIG. 15. Representative
dose-response curve of the
MN viral isolate with a
panel of monoclonal
antibodies. Approximate
IC50, 80, and 90 values are
indicated for the b12 Fab.
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Table 7. HIV-1 single round in vitro neutralization assay of anti-envelope glycoprotein antibodies against a
panel of viral isolates. IC50, 80, and 90 values represent the concentration of antibody (µg/ml) required for the
reduction of infection by 50, 80, or 90 %, respectively. (A) Anti-gp120 Fab antibodies. (B) Anti-gp41 IgG
antibody. ND: Not detectable.
A viral b12 Fab CG5 Fab
isolate Clade IC50 IC80 IC90 IC50 IC80 IC90
IIIB B 0.9 3.7 8.8 4.7 >200 >200
MN B 0.0 0.1 0.1 0.7 4.3 12.6
SF162 B 0.5 1.4 2.8 6.7 139.6 >200
BaL B 1.7 4.0 6.8 8.1 >200 ND
ADA B 8.0 53.2 163.0 14.6 >200 >200
89.6 B 0.2 1.1 1.7 >200 ND ND
JR-CSF B 1.5 4.0 7.4 >200 >200 ND
JR-FL B 0.3 1.3 3.1 50.8 >200 >200
YU2 B 9.2 43.6 112.4 ND ND ND
ZA012 C ND ND ND 27.6 >200 >200
viral F91 Fab CG9 Fab
isolate Clade IC50 IC80 IC90 IC50 IC80 IC90
IIIB B 34.8 >200 >200 6.0 >200 >200
MN B 1.0 6.4 18.9 0.9 4.6 12.0
SF162 B 57.8 >200 >200 10.8 >200 >200
BaL B >200 ND ND 15.6 >200 >200
ADA B 152.0 >200 >200 38.3 >200 >200
89.6 B >200 ND ND 169.1 >200 >200
JR-CSF B >200 ND ND >200 >200 ND
JR-FL B >200 >200 >200 54.7 >200 >200
YU2 B ND ND ND ND ND ND
ZA012 C ND ND ND 24.9 >200 >200
viral F105 Fab CG21 Fab
isolate Clade IC50 IC80 IC90 IC50 IC80 IC90
IIIB B 99.6 >200 >200 26.1 >200 >200
MN B 178.5 >200 >200 1.8 12.5 37.7
SF162 B 94.0 >200 >200 35.9 >200 >200
BaL B >200 >200 ND 32.9 >200 >200
ADA B >200 >200 ND >200 >200 >200
89.6 B >200 ND ND >200 ND ND
JR-CSF B ND ND ND >200 >200 ND
JR-FL B >200 >200 >200 >200 >200 >200
YU2 B ND ND ND ND ND ND
ZA012 C ND ND ND 57.3 >200 >200
B viral 4E10 IgG
isolate Clade IC50 IC80 IC90 Color key:
IIIB B 6.4 99.5 >200
MN B 0.3 2.1 6.5 <  1 
SF162 B 8.6 103.3 >200
BaL B 3.8 68.6 >200 < 10
ADA B 8.2 73.2 >200
89.6 B 1.9 14.0 44.0 <100
JR-CSF B 10.0 167.9 >200
JR-FL B 2.1 14.9 46.1
YU2 B 5.9 63.3 >200
ZA012 C 11.7 140.7 >200
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The CD4 binding site antibody F105 has previously been shown to neutralize
TCLA-isolates with moderate potency (77), but not primary isolate viruses. This
phenotype could be reproduced in this neutralization assay, with Fab F105 being able to
significantly neutralize (IC50 <100µg/ml) only the TCLA-isolate IIIB and the primary
isolate that is the most neutralization-sensitive in the viral panel examined here, SF162.
The Fab fragment of the F91 antibody exhibited slightly greater breadth and potency of
neutralization than Fab F105. Fab F91 neutralized, in addition to IIIB and SF162, the
TCLA isolate MN, with an IC50 of 1µg/ml. It exhibited generally greater potency than
Fab F105 with IC50 values for the neutralization of IIIB, MN, and SF162 of 34.8, 1, and
57.8, respectively. Consistent with previous reports, the potent neutralizer Fab b12
displayed the by far greatest breadth and potency of neutralization of all tested antibodies.
Fab b12 was able to significantly neutralize all viral isolates except the clade C isolate
ZA012. The IC50 of Fab b12 for the neutralization of the TCLA isolates IIIB and MN as
well as the primary isolates 89.6 and JR-FL were below 1µg/ml, and IC90 was achieved at
10µg/ml for all tested clade B isolates but ADA.
The Fab fragments CG5, CG9, and CG21 were found to be intermediate in
neutralization breadth and potency, between that of Fab b12 and the Fab fragments of
F91 and F105. The neutralization profiles of CG5 and CG9 were similar, with significant
neutralization being observed with the TCLA isolates as well as five primary isolates
(SF162, BaL, ADA, JR-FL, and ZA012). CG21 exhibited less potency and breadth than
CG5 and CG9 and was not able to significantly neutralize the primary isolates ADA and
JR-FL. The IC50 values of CG5 for the neutralization of IIIB, MN, SF162, and BaL were
below 10µg/ml, whereas IC50 values for F91 in this concentration range were obtained
only for MN. Notably, CG5, CG9, and CG21 were able to neutralize the clade C isolate
ZA012 with IC50s of 27.6, 24.9, and 57.3, respectively, whereas no other tested Fab could
significantly neutralize this isolate. Only Fab b12 was able to neutralize the primary
isolate YU2, although the Fabs CG5, CG9, and CG21 had been selected against envelope
glycoproteins derived from this isolate. All Fabs showed enhancement of infection with
YU2, with Fab b12 exhibiting slight enhancement only at concentrations of under 1µg/ml
and neutralization at higher antibody concentrations. For the other Fabs, the enhancement
of infection generally increased with increasing amounts of Fab at the lower
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concentrations of 0.004, 0.04, 0.2 and 1µg/ml and plateaued at approximately 60%
enhancement of infection at higher Fab concentrations (data not shown).
The neutralization breadth of the gp41 binding IgG 4E10 was found to be similar
to that of Fab b12, with 4E10 also significantly neutralizing the clade C isolate ZA012.
However, 4E10 displayed generally lower potency than did Fab b12. The neutralization
profiles of the Fabs CG5 and CG9 were found to resemble that of 4E10, although the
Fabs displayed less potency and not as broad neutralization as 4E10.
3.3.4 Neutralization of in vitro HIV-1 infection by Fabs versus IgGs
Fab fragments of antibodies have previously been shown to exhibit different
binding affinities and neutralization potency compared to whole antibodies due to avidity
effects. Therefore, the difference in neutralization potency of Fab fragments and their
respective whole antibody counterparts was examined. Fab fragments of the human
antibodies IgG1b12, F105, and F91 were generated biochemically and tested for their
neutralization potency and breadth against the previously used panel of viral isolates
(Table 8).
Table 8. HIV-1 single round in vitro neutralization assay comparing the neutralizing activity of Fab and
IgG antibodies against a panel of viral isolates. The concentration of antibody required to achieve 50%
reduction of infection (IC50) are given. ND: Not detectable.
µg/ml to achieve 50 % reduction of infection
b12 F105 F91
Isolate Clade Fab IgG Fab IgG Fab IgG
IIIB B 0.9 0.1 99.6 6.9 34.8 35.8
MN B 0.0 0.0 178.5 11.2 1.0 1.8
SF162 B 0.5 0.2 94.0 10.8 57.8 42.8
BaL B 1.7 0.3 >200 47.0 >200 >200
ADA B 8.0 0.9 >200 60.4 152.0 >200
89.6 B 0.2 0.1 >200 46.4 >200 29.7
JR-CSF B 1.5 0.5 ND 76.3 >200 88.9
JR-FL B 0.3 0.0 >200 158.5 >200 >200
YU2 B 9.2 0.7 ND ND ND ND
ZA012 C ND 178.3 ND 31.9 ND >200
µg/ml to achieve 50% reduction of infection
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The neutralization potency of b12 and F105 whole antibodies was consistently
higher than that of the corresponding Fab fragments. The antibody IgG1b12 inhibited
infection more efficiently than did the Fab fragment with between 2- to 13-fold lower
IC50 values for the neutralization with whole antibody. The gain in neutralization potency
of the whole antibody F105 over the Fab fragment was more pronounced, with up to 16-
fold lower IC50 values for neutralization with the whole antibody. The differences in
neutralization by F91 between whole antibody and Fab fragment were less consistent,
with better neutralizing activity of the whole antibody over the Fab fragment only
observed for the isolates 89.6 and JR-CSF. Compared to projected IC50 values (data not
shown) for the F91 Fab fragment, these two isolates were neutralized at IC50 values 60-
and 4600-fold lower than for the whole antibody, respectively. The ADA isolate was
neutralized better by the Fab fragment than the IgG, with projected IC50 values 9.4-fold
lower than for the Fab F91. The projected IC50 values, however, should only be
interpreted as rough estimates. For all other isolates, where determined, the IC50 values
for neutralization with F91 Fab and IgG were similar.
3.4 Envelope glycoproteins deficient in T-cell helper epitopes
Viral escape from recognition by CD8+ T-lymphocytes is a well documented
phenomenon. It is conceivable that escape of viruses from recognition by CD4+ T-helper
cells would also endow a virus with a replicative advantage. Escape from CD4+ T-helper
cells recognition, however, has not yet been described for HIV.
In preliminary experiments, gp120 core+V3 envelope glycoproteins
(∆82∆V1,2∆C5) (Fig. 16) were generated to test if these glycoproteins would more
efficiently elicit neutralizing antibodies against conserved elements maintained in the
gp120 core than full-length gp120. BALB/c mice were immunized with core gp120
envelope glycoprotein derived from the TCLA isolate HXBc2 and the primary isolate
YU2. Although a detectable anti-gp120 antibody response was elicited by the HXBc2
core gp120, the YU2 core gp120 elicited no detectable antibody response (data not
shown). To determine if this nonresponder phenotype could be observed in another
mouse strain, and to explore the reasons for the defect of the primary isolate-derived core
gp120 to elicit antibodies, the experiment was repeated in C57BL/6 mice.
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FIG. 16. Schematic representation of full length (A) and core gp120 (B). Glycosylation sites are indicated
as branched chains. Constant and variable regions are labeled C1-5 and V1-5. Regions deleted in the core
gp120 are shaded (B). Amino acid numbering does not include the signal peptide (30 amino acids).
3.4.1 Anti-gp120 IgG reactivity in mouse sera raised against YU2 core gp120 and
HXBc2 core gp120
Groups of six C57BL/6 mice were inoculated four times with 20 µg of YU2 core
gp120 and HXBc2 core gp120. The anti-gp120 IgG reactivity in the sera raised against
recombinant YU2 or HXBc2 core gp120 was determined by ELISA (Fig. 17). Mice
immunized with the TCLA isolate-derived core gp120 (HXBc2) displayed high titers of
anti-gp120 reactive IgG with an endpoint titer of greater than 100,000. The anti-gp120
IgG titers detected in sera raised against the primary isolate YU2 core gp120 was only
minimally higher than the anti-gp120 reactivity of preimmune serum, even at the lowest
serum dilution of 1:100. To explore if the lack of a gp120 IgG response is a general
phenomenon that extends to other primary isolate core gp120, core gp120 derived from
the primary isolate JR-FL was produced and inoculated into BALB/c mice as described
above. A similarly low anti-gp120 IgG response was also observed in the sera of mice
immunized with JR-FL gp120 (data not shown).
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FIG. 17. ELISA of anti-gp120 IgG reactivity of mouse sera raised against HXBc2 core gp120 (left panel)
and YU2 core gp120 (right panel). Mice were inoculated four times with HXBc2 core gp120 or YU2 core
gp120. Sera were tested against HXBc2 core gp120 and YU2 core gp120 antigen, respectively.
3.4.2 Generation of fusion proteins of core gp120 and the heterologous helper epitope
PADRE
To test if the absence of serum IgG reactivity against core gp120 derived from the
primary isolate YU2 was due to a lack of T-helper epitopes in this protein, both HXBc2 
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and YU2 core gp120 molecules were expressed as fusion proteins with two repeats of the
heterologous helper epitope PADRE, one each appended on the C- and N-terminus. To
confirm the presence of the PADRE sequences on the core gp120, the proteins were
subjected to 12% SDS-PAGE analysis (Fig. 18). A difference in electrophoretic mobility
between the core gp120 and the core-PADRE gp120 could be detected. This difference in
mobility corresponded to the difference expected for the core gp120 proteins and the
fusion proteins carrying two repeats of PADRE with an additional molecular weight of
approximately 2.6 kD.
3.4.3 Anti-gp120 IgG reactivity in mouse sera raised against YU2 and HXBc2 core
gp120 and core-PADRE gp120
To test if the addition of heterologous helper epitopes restores the
immunogenicity of the primary isolate-derived core gp120, YU2 core gp120 and core-
PADRE gp120 were inoculated into groups of six C57BL/6 mice. This strain of mice was
chosen because they express the MHC class II I-Ab allele that has been shown to bind the
PADRE epitope with high affinity (2). HXBc2 core gp120 and HXBc2 core-PADRE
gp120 were inoculated similarly. After four inoculations, anti-gp120 IgG serum titers
were determined by ELISA (Fig. 19). The anti-gp120 titers raised against the HXBc2
core gp120 and core-PADRE gp120 were similar, with endpoint titers of greater than
100,000, indicative of no obvious effect on immunogenicity of the PADRE epitope on
this core gp120. The titers raised against YU2 core-PADRE gp120, in contrast, were
substantially higher than the titers raised against the core gp120. The anti-gp120 titers of
YU2 core-PADRE gp120 immune serum exhibited endpoint titers of greater than
100,000 compared to preimmune serum. These titers were similar to those observed for
the immune and preimmune sera of the animals inoculated with HXBc2 core gp120,
whereas the YU2 core gp120 did not elicit a detectable anti-gp120 antibody response.
These data suggest that the addition of the heterologous helper epitope PADRE fully
restored the immunogenic potential of the YU2 core gp120.
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FIG. 19. ELISA of anti-gp120 IgG reactivity of mouse sera raised against core gp120 and core-PADRE
gp120 from HXBc2 and YU2. Mice were inoculated four times with HXBc2 core gp120 and core-PADRE
gp120 (left panel) or YU2 core gp120 and core-PADRE gp120 (right panel). Sera were tested against
HXBc2 core gp120 and YU2 core gp120 antigen, respectively.
Although the titer of anti-gp120 IgG raised in mice inoculated four times with
HXBc2 core gp120 and core-PADRE gp120 appeared to be unaffected by the addition of
PADRE, a clear difference in titers raised against the two gp120 could be observed after 
one inoculation and, most pronounced, after two inoculations (Fig. 20). When pooled
serum from the two groups were analysed, the endpoint titer generated by the HXBc2
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core-PADRE gp120 envelope glycoprotein were greater than 100,000, whereas the
enpoint titer of the HXBc2 core gp120 was 400.
3.4.4 Serum reactivity against PADRE, neoepitopes, and carbohydrate moieties
To rule out the possibility that the increase in serum reactivity observed in sera
raised against YU2 core-PADRE gp120 compared to YU2 core gp120 was due to
reactivity of these sera against the PADRE epitope itself or neoepitopes created by the
fusion of PADRE with the core gp120, reactivity of serum raised against YU2 core-
PADRE gp120 was tested by ELISA for reactivity to YU2 core gp120 and YU2 core-
PADRE gp120 antigen. The reactivity of serum raised against YU2 core-PADRE gp120
to YU2 core gp120 antigen was roughly equivalent to the reactivity to the YU2 core-
PADRE gp120 antigen (Fig. 21). Thus, the increased anti-gp120 reactivity observed in
serum raised against YU2 core-PADRE gp120 is not due to reactivity against PADRE or
neoepitopes spanning the PADRE-core junction.
Heterologous helper epitopes are capable of breaking natural immunologic
tolerance against self-determinants (32). The gp120 envelope glycoprotein is heavily
glycosylated with about half of its molecular weight being contributed by carbohydrate
moieties. Since this glycosylation is catalyzed by the host glycosylation system, the
carbohydrate moieties are likely considered "self" by the human immune system.
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Breaking tolerance to these moieties may generate a substantial anti-carbohydrate
antibody response that would represent a trivial explanation for the effects of the
heterologous helper epitope observed here. Anti-self carbohydrate reactivities would not
be selectively directed against virus and therefore would be highly undesirable in a
vaccine setting. Consequently, we tested the possibility that the addition of PADRE
FIG. 22. ELISA of IgG reactivity against wild-type (WT) and deglycosylated core gp120 antigen. Mouse
serum was collected after four inoculations with HXBc2 core gp120, HXBc2 core-PADRE gp120, and
YU2 core-PADRE gp120, respectively, and tested for reactivity with WT and enzymatically
deglycosylated homologous core gp120 antigen.
sequences increases the generation of carbohydrate-directed antibodies rather than
antibodies directed against viral protein determinants. Sera raised in mice against HXBc2
core gp120, HXBc2 core-PADRE gp120 and YU2 core-PADRE gp120 were tested for
IgG reactivity against wild-type (WT) gp120 and enzymatically deglycosylated gp120
derived from the same strain by ELISA (Fig. 22). Some degree of carbohydrate reactivity
to the glycosylated gp120 when compared to the deglycosylated gp120 could be observed
in all sera, even those elicited by the HXBc2 cores not containing PADRE. Since all sera
exhibited carbohydrate reactivity, this may represent a baseline carbohydrate reactivity
generally raised by gp120, or a quantitative difference in the amounts of WT and
deglycosylated input gp120 antigen.
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FIG. 23. D-mannose inhibition ELISA. (A) Binding of the monoclonal antibodies 2G12, IgG1b12
(5µg/ml), and preimmune rabbit serum (Pb, 1:1000 serum dilution) to Drosophila gp120 in the presence of
increasing amounts of D-mannose. (B) Binding of rabbit sera raised against core-PADRE gp120 (animals
1-5, 1:1000 serum dilution) in the presence of increasing amounts of D-mannose.
To further examine carbohydrate reactivity, sera raised in rabbits against core-
PADRE gp120 were tested in a competition ELISA using monomeric D-mannose. The
2G12 antibody was used as a control. This antibody has recently been shown to bind to a
cluster of D-mannose moieties in the proximity of the C4/V4 region of gp120 (94, 98,
112). D-mannose competed with 2G12 for binding to gp120 expressed in Drosophila S2
cells in a dose-dependent manner (Fig. 23A). At a concentration of 0.5M D-mannose,
2G12-binding to gp120 was completely inhibited. No D-mannose competition for
binding of gp120 was observed with the CD4BS antibody IgG1b12 that recognizes gp120
in a carbohydrate-independent manner. Binding of sera raised against core-PADRE
gp120 was only minimally inhibited by D-mannose at the highest concentration tested,
suggesting low carbohydrate reactivity elicited by the Drosophila high-mannose glycans
on gp120 (Fig. 23B). Thus, it is likely that no or only slight additional carbohydrate
reactivity was generated by the addition of PADRE sequences.
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3.4.5 Anti-gp120 IgG and IgM reactivity in rabbit serum
A strong deficiency of the core gp120 of the primary isolate YU2 and JR-FL to
elicit anti-gp120 IgG in mice was observed. This lack of an IgG response could be
restored by the addition of heterologous T-helper epitopes. Both strains of mice,
however, possess a very limited number of MHC II alleles; I-Ab in the C57BL/6 mice and
I-Ad and I-Ed in the BALB/c mice.
To exlude the possibility that the observed deficiency in T-helper epitopes of the
primary isolate YU2 core gp120 is an effect only manifest in the context of a limited
MHC class II background, YU2 core gp120 and YU2 core-PADRE gp120 were
inoculated into outbred rabbits. Groups of five New Zealand White rabbits were
inoculated with 20 µg of gp120 and serum was collected after each inoculation following
the priming. The sera were tested for anti-gp120 IgG-reactivity by ELISA (Fig. 24).
Generally, the same poor elicitation of an anti-gp120 antibody response by the YU2 core
gp120 was observed as before in C57BL/6 and BALB/c mice. The serum raised against
YU2 core-PADRE gp120 showed consistently higher anti-gp120 reactivity than did the
YU2 core gp120 serum. The YU2 core gp120, however, did elicit slightly higher
antibody titers in rabbits compared to mice; the helper epitope deficiency appeared less
pronounced in this particular MHC class II context. As previously observed with the
HXBc2 core gp120 and HXBc2 core-PADRE gp120, the difference between titers raised
against YU2 core gp120 and YU2 core-PADRE gp120 diminished slightly from the third
inoculation to the fourth inoculation. When endpoint titers were determined relative to
prebleed serum of the respective animals after the third and fourth inoculation, sera raised
against YU2 core-PADRE gp120 displayed endpoint titers of >62,500 compared to
endpoint titers raised with the YU2 core gp120 at >2500 (Fig. 24A). In the group
immunized with YU2 core gp120, animal # 54 displayed strong anti-gp120 IgG reactivity
that was almost as high as the anti-gp120 serum reactivity observed in the YU2 core-
PADRE gp120 group. The particular MHC class II repertoire of this animals may bind
and present endogenous gp120 helper epitopes that the other four animals in this group
may not recognize. The fact that the #54 rabbit immunized with YU2 core gp120 exhibits
titers similar to the rabbits immunized with YU2 core-PADRE indicates that the
pronounced differences observed with core gp120 and core-PADRE gp120 are not
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FIG. 24. ELISA of IgG reactivity against YU2 gp120 in rabbit sera. Serum was collected after two, three,
and four inoculations with YU2 core gp120 and YU2 core-PADRE gp120, respectively, and anti-gp120
reactivity was tested against YU2 gp120 antigen. Panel A: The average of anti-YU2 gp120 IgG reactivity
of five rabbits inoculated with YU2 core gp120 and core-PADRE gp120 are shown. Panel B: The anti-
gp120 IgG reactivity of the responder animal #54 from the group inoculated with YU2 core gp120 is
plotted separately.
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merely due to dose differences. Rather, they are indicative of a difference in the MHC II
haplotype. When the responder animal #54 was individually plotted and compared to the
core gp120 and core-PADRE gp120 groups, the difference between the two groups
became more pronounced (Fig. 24B). After inoculation three, the endpoint titer for the
core-PADRE gp120 group was >62,500, whereas the endpoint titers in the core gp120
group were >2500 with and >500 without the responder animal #54.
To assess the anti-gp120 IgM reactivity in sera raised against the core gp120,
serum of rabbits inoculated with YU2 core gp120 and YU2 core-PADRE gp120 was
tested by ELISA. Generally, similar low titers of anti-gp120 IgM could be detected in all
animals (data not shown).
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4 Discussion
The inability of HIV-1 gp120 envelope glycoproteins to either elicit broadly
neutralizing antibodies or to efficiently select inhibitory ligands from libraries has
hampered efforts to develop reagents that intervene in viral envelope glycoprotein-
receptor interactions. Recent reports have demonstrated that soluble oligomeric envelope
glycoprotein constructs possess characteristics consistent with the trimeric structures
found on the surface of virus or infected cells (122). An immunogenicity study with one
particular construct, trimeric YU2 gp140-GCN4 glycoproteins, demonstrated that the
trimeric construct better elicits neutralizing antibodies when compared to monomeric
gp120 (125). These results support the notion that proteins that more faithfully mimic the
structure of the viral envelope glycoprotein complex may more efficiently elicit
neutralizing antibodies and may also be more efficient in identifying neutralizing
antibodies from libraries.
4.1 Generation of proteoliposomes
Because of these possible advantages as an immunogen, an oligomeric envelope
glycoprotein formulation has been designed, solid-phase proteoliposomes, in an attempt
to most closely mimic the trimeric envelope glycoprotein complex found on the surface
of the virus or on the surface of envelope glycoprotein-expressing cells. The approach
pursued here was to reduce the mutational changes introduced into the envelope
glycoproteins to a minimum and to retain the homologous trimerization and
transmembrane domains. This could be achieved by reconstitution of a lipid bilayer
around the proteoliposomes.
The proteoliposomes described here possess native gp160∆CT glycoproteins, as
assessed by extensive FACS analysis with conformationally-sensitive ligands. The
gp160∆CT glycoproteins captured on the proteoliposomes are cleavage-defective and
thereby possess a covalent linkage between gp120 and gp41 subunits, which enhances
spike stability. The envelope glycoproteins exist primarily as trimers on the
proteoliposome surface as determined by elution and size-exclusion chromatography
under non-denaturing conditions. As opposed to soluble trimeric GCN4-stablized
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constructs (122, 123), the native gp41 oligomerization domain in the context of the lipid
bilayer is sufficient to maintain the trimeric conformation and no heterologous
trimerization motifs need to be appended to the gp160∆CT glycoprotein. The
reconstituted lipid bilayer may provide advantages over the soluble gp140 glycoproteins
by both stabilizing known gp41 neutralizing determinants as well as limiting access by
antibody to non-neutralizing envelope glycoprotein determinants.
Other approaches, such as the use of virus-like particles (VLPs), also allow for the
formulation of envelope glycoproteins as membrane-associated, native entities. However,
as VLPs bud from the cell surface, cellular proteins other than envelope glycoproteins are
incorporated into VLPs, limiting the purity of these preparations. The well-defined
protein content of the proteoliposomes described here provides an advance over
traditional VLPs, as the affinity capture-purification method renders the proteoliposomes
practically devoid of other cellular components. Also, since the bead core of the
proteoliposomes is optimized for binding of protein at high density, the protein density on
the surface of the proteoliposomes is likely much greater than that found on VLPs. The
proteoliposomes have properties that allow for their use in probing libraries of biological
or chemical compounds, including phage display libraries. Their paramagnetic properties,
although not an absolute requirement for their composition, allow for the fast and
complete recovery of the proteoliposomes from complex mixtures.
Antigenically, proteoliposomes are virtually indistinguishable from envelope
glycoproteins present on the cell surface of gp160∆CT-expressing cells. For some anti-
gp120 ligands, namely IgG1b12 and sCD4, the affinity towards envelope glycoproteins
on proteoliposomes is marginally but reproducibly higher than that to envelope
glycoproteins expressed on the cell surface. This might be due to better accessibility of
the envelope glycoproteins on proteoliposomes as a consequence of the lack of other
masking proteins and glycocalix components.
The de novo generation of a lipid bilayer around the individual beads has
previously been shown to be an effective method to retain functionality and
conformational integrity of the seven-transmembrane proteins CCR5 (64) and CXCR4
(7). When formulated as proteoliposomes, the seven-transmembrane CCR5 molecule
retained native structure and could withstand changes in salt and pH that denatured
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detergent-solubilized CCR5 (64). For the gp160∆CT proteoliposomes, reconstitution of
the membrane was dependent on the presence of gp160∆CT glycoprotein on the bead,
suggesting that the lipid does not bind to the bead non-specifically but rather forms in a
coordinated fashion. The hydrophobic transmembrane regions of the envelope
glycoprotein likely nucleate membrane formation during the reconstitution.
The binding of a secondary antibody to the 1D4 capture-antibody was
significantly reduced by membrane reconstitution. This indicates that, at least in part, the
lipid bilayer was reconstituted around the protein constituents captured on the bead. That
the membrane interacts with elements in the gp160∆CT transmembrane region is
supported by the 2F5 antibody binding profiles on proteoliposomes with reconstituted
membranes versus proteoliposomes without membrane. The neutralizing antibody 2F5
recognizes a linear epitope in the gp41 ectodomain (ELDKWAS) directly adjacent to the
transmembrane region (80). The comparison of binding of 2F5 to gp160∆CT on
proteoliposomes versus beads without a reconstituted membrane shows a roughly ten-
fold higher affinity towards the epitope on the membrane-embedded envelope
glycoprotein. Such an affinity difference was not seen with the F105 or 2G12, two
gp120-directed antibodies (Fig. 10). Although the 2F5 epitope appears to be linear, it
might exhibit some dependence upon conformation. These requirements of the important
but elusive 2F5 epitope seem to be better retained by reconstitution of the lipid
environment.
In conclusion, the data presented strongly suggest that the gp160∆CT
proteoliposomes provide a native conformation of HIV-1 envelope glycoproteins in a
suitable format to test these unique reagents as immunogens or to select for novel ligands
from phage display antibody libraries. The gp160∆CT proteoliposomes should also be
useful for studies of purified HIV-1 envelope glycoproteins in a natural context.
4.2 Proteoliposomes as immunogens
The elicitation of broadly neutralizing antibodies against the HIV-1 envelope
glycoproteins remains a major challenge. Monomeric gp120 has proven to be a poor
immunogen. To date, only few envelope glycoprotein formulations have been shown to
more effectively elicit broadly neutralizing antibodies than monomeric gp120 (125). A
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recent study suggests that complexes of monomeric gp120 and soluble CD4 better elicit
broadly neutralizing antibodies than does monomeric gp120 in a primate model (40).
However, part of the antibody response generated by these complexes is directed against
CD4. Anti-CD4 antibodies have been shown to be highly efficient in broadly neutralizing
HIV-1 (47, 96). The elicitation of such reactivities in vaccinated individuals, however, is
not desirable.
The complex and labile organization of the functional trimeric envelope
glycoprotein complex poses difficulties for the design of faithful antigenic mimics of
these complexes. Here, we tested proteoliposomes as novel immunogens for their ability
to elicit broadly neutralizing antibodies in outbred rabbits. A study by Yang et al.
demonstrated an ability of a YU2 gp140-GCN4 construct to elicit neutralizing antibodies
with limited breadth in mice. Therefore, we tested this construct side-by-side with
proteoliposomes and monomeric YU2 gp120 in a comparative immunogenicity study.
The molecular clone YU2 was chosen for the preparation of proteoliposomes for
immunization studies because it exhibits one of the most neutralization-resistant
phenotypes. This molecular clone was not passaged in tissue culture prior to molecular
cloning (55) and can only poorly be neutralized by antibodies and soluble forms of the
CD4 receptor. In contrast, YU2 often exhibits significant enhancement of infection by
these ligands (104, 106). It was hypothesized that breadth of neutralization would most
likely be exhibited by antibodies that are raised against neutralization-resistant molecular
clones, with neutralization extending from there to more neutralization-sensitive clones.
By deriving the envelope glycoproteins for the generation of proteoliposomes
from the YU2 molecular clone, the immunogenicity of proteoliposomes could be directly
compared to that of the previously tested immunogen YU2gp140-GCN4. Thus, it could
be assessed if the proteoliposomes represent an advance over existing envelope
glycoprotein constructs. There is, however, one caveat to this direct comparison. The
dose of envelope glycoprotein that could be inoculated into rabbits with soluble
YU2gp140-GCN4 constructs was approximately 5-fold greater than the amount of
envelope glycoproteins formulated as proteoliposomes.
To assess the total amount of IgG antibody elicited by the different immunogens,
sera was tested by anti-gp120 ELISA. Interestingly, although the dose of envelope
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glycoproteins administered into animals receiving proteoliposomes was approximately 5-
fold lower, these animals generated similar endpoint ELISA titers compared to the
animals inoculated with soluble envelope glycoproteins (Table 2). The particulate
presentation of envelope glycoprotein as proteoliposomes to the immune system may be
more effective for the elicitation of antibodies than the administration of soluble protein.
One possible explanation for this may be a depot effect of the proteoliposome
formulation that better prevents the dilution and clearance of protein immunogen by
physically immobilizing and sequestering the immunogen in the tissue at the site of
inoculation. This depot effect is also facilitated by the addition of detergent-containing
adjuvant, such as the Ribi adjuvant used here, but may not be as efficient as particulate
formulation of the immunogen. Also, there may be more efficient uptake of immunogen
by antigen-presenting cells if the immunogen is particulate rather than soluble.
Overall, the oligomeric envelope glycoprotein formulations displayed greater
neutralizing activity than did monomeric gp120. The neutralizing activity of sera in each
group was very diverse although trends could be observed. Homologous neutralization of
the YU2 virus generally corresponded with neutralization of the SF162 isolate and, in
most cases, the HXBc2 isolate. Conversely, neutralization of HXBc2 or SF162 did not
necessarily correspond with homologous YU2 neutralization. This observation is
consistent with the initial rationale for choosing YU2 for the generation of immunogens.
Neutralizing antibodies raised against a neutralization-resistant viral isolate appear to
have a greater propensity to neutralize other viral isolates than antibodies raised against a
more neutralization-sensitive viral isolate (125).
There may be several reasons for the better ability of the trimeric glycoprotein
formulations (YU2 gp140-GCN4 and proteoliposomes) to elicit neutralizing antibodies
when compared to monomeric gp120. The first reason may be that these oligomeric
molecules were derived from a primary isolate (YU2), which is highly resistant to most
neutralizing antibodies and in particular to strain-restricted V3 loop-directed antibodies.
The second possibility is that the trimeric molecules may reduce the conformational
flexibility seen with monomeric gp120 and thereby more efficiently elicit antibodies that
recognize the functional trimer. By titration microcalorimetry, it was previously shown
that gp120 exhibits a large loss of entropy following interaction with CD4 (70). As this
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entropy loss is not dependent on the major gp120 variable loops V1, V2 or V3, it is likely
that the flexibility detected by the thermodynamic analysis involves the core domains of
gp120. This flexibility may contribute to the elicitation of many antibodies that do not
cross react with the native trimer. In fact, most antibodies elicited in infected individuals
or vaccinated subjects bind with high affinity to monomeric gp120 but not to oligomeric
gp120 found on the surface of infected cells (41, 83, 97). Thirdly, the inclusion of gp41
protein sequences might provide additional T-helper epitopes that might quantitatively
increase anti-envelope antibody levels. Finally, oligomeric antigens may more effectively
trigger immune responses than monomers as they might better be able to crosslink
antigen receptors and thus provide better activation signals.
An enhancing effect of immune sera on YU2 infection could be readily observed
in all groups. Enhancement of HIV-1 infection by antibodies binding at subsaturating
concentrations has been well described (49, 56, 87, 104, 105, 108). Antibody binding to
virus can lead to Fc-receptor mediated endocytosis and infection. Also, antibody binding
to Fc-receptors may stabilize the interaction of the virus and the target cell's receptor,
providing a nonspecific binding component. Complement-mediated modes of
enhancement have also been described. These mechanisms, however, cannot easily
explain the envelope-specific enhancement observed, especially since enhancement of
infection observed here and elsewhere (104) could also be mediated by Fab fragments.
Another model suggests that antibodies at subsaturating concentrations may induce
conformational changes that may allow for more efficient binding to the cellular
receptors.
Neutralization of YU2 greater than 90% was achieved by only two animals at the
serum dilution tested. The isolates 89.6, BAL, and ADA could not be neutralized by any
of the sera tested (with animal 24 neutralizing 89.6, but the unusual enhancement with
preimmune serum calls this result into question). Interestingly, only one animal
inoculated with proteoliposomes neutralized the homologous isolate YU2, while the
isolates HXBc2 and SF162 were readily neutralized by four out of five and five out of
five animals in this group, respectively. Homologous neutralization is likely mediated by
variable loop-directed antibodies, whereas cross-neutralization that extends to
heterologous strains is usually associated with antibodies directed against conserved
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epitopes such as the CD4 binding site. This raises the possibility that proteoliposomes are
more efficient in raising antibodies that bind conserved envelope glycoprotein structures
than variable loop-directed antibodies. Thus, homologous neutralization may not be
achieved in these animals due to a lack of variable loop-directed antibodies and titers of
CD4BS antibodies too low to neutralize the neutralization-resistant YU2 isolate. This
possibility will be tested by analysis of the specificity of monoclonal antibodies generated
from individual animals from each group.
When the animals were inoculated for a fifth time after an extended resting
period, no consistent boosting effect could be observed (Table 4). In general, higher
nonspecific neutralization of preimmune serum could be observed after the fifth
inoculation (data not shown) and may be indicative of a generally elevated immune status
in these animals. Some animals that had been inoculated with PLs developed signs of a
general inflammatory response and some hematomas. The higher neutralization by
preimmune serum, however, was also observed in the groups inoculated with soluble
protein. Whereas some animals displayed better neutralization after the fifth inoculation
compared to the fourth inoculation, some animals displayed decreasing neutralizing
activity. Since the quality of the immunogen was monitored before each inoculation and
was not found to deteriorate during the course of the immunization experiment, other
factors may account for this effect. In the course of an antibody response, affinity
maturation selects for the antibodies with the highest affinity for the immunogen (1, 51).
This selection process is strictly affinity-driven. There is no selection for antibodies with
neutralizing activity. With progressive maturation of the antibody response, high-affinity
antibodies are elicited. Neutralizing antibodies, however, may not necessarily be of high
affinity and might become less abundant. Therefore, an immunization protocol that limits
the number of boosts may be more effective. This hypothesis will be tested by boosting
the animals for a sixth time to see if a general trend towards less neutralizing activity
becomes apparent.
Although increasing the number of inoculations does not seem to be consistently
beneficial to raise neutralizing antibody titers, increasing the dose of immunogen at each
inoculation may very well be. The less efficient elicitation of neutralizing antibodies
observed with proteoliposomes compared to YU2 gp140-GCN4 may be due to the
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smaller dose of envelope glycoproteins inoculated. The optimization of the
proteoliposome formulation towards an increased amount of envelope glycoproteins
incorporated per volume unit, for example by decreasing bead size, would address this
limitation.
The sera generated in the different immunizations were tested for neutralization of
HIV-1 in in vitro single-round neutralization assays. These assays are useful as initial
screens for the evaluation of immunogens. There are, however, inherent problems of this
kind of assay that limit the predictive value of the obtained data. Animal serum is a
highly heterogenous mixture containing immune effector molecules such as complement
and cytokines that impact on the readout of the assay. These nonspecific components of
serum can cause a broad range of effects, from enhancement of HIV-1 infection to
significant neutralization, depending on the genetic variation and immune status of
individual animals. These effects can mask specific, antibody-mediated effects and
therefore limit the fidelity of the assay. It is therefore necessary to carefully control for
nonspecific serum effects and to monitor the influence of individual preimmune serum.
Here, neutralization of immune serum was monitored against the background of
nonspecific enhancement or neutralization of infection observed with preimmune serum
from individual animals. To limit nonspecific effects of serum and yet retaining high
enough concentrations of specific antibodies, serum was tested in neutralization assays at
a dilution of 1:5. Although the data obtained were reproducible and internal controls were
included, due to inherent variation from animal to animal, these data need to be
interpreted with caution.
This study adds strong evidence in support of the concept that trimeric envelope
glycoprotein formulations are more efficient in eliciting broadly neutralizing antibodies.
The data presented here demonstrate that two trimeric envelope glycoprotein
formulations, proteoliposomes and soluble YU2 gp140-GCN4 ectodomain constructs,
better elicit broadly neutralizing antibodies than monomeric gp120. The proteoliposome
format holds promise to be an advance in immunogen design if the current dose-related
limitations can be overcome.
In a previous study, the YU2 gp140-GCN4 construct was shown to better elicit
broadly neutralizing antibodies than gp120 in mice (125). However, to be able to predict
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the efficacy of this immunogen in humans, it is of vital importance to extend and validate
these findings to different animal models with a more diverse MHC background. In this
study, we show that the improved elicitation of broadly neutralizing antibodies with YU2
gp140-GCN4 constructs also translates to outbred animals. Thus, this study supports and
extends the previous immunogenicity data by reproducing the neutralization data
obtained in a mouse model and extending these data to a more diverse MHC context.
These findings document that trimeric envelope glycoprotein formulations are a
promising step towards designing an HIV-1 subunit vaccine.
4.3 Proteoliposomes as antigens
Broadly neutralizing antibodies have proven to be a powerful tool for the study
and design of immunogens, understanding the mechanisms of neutralization, and the
mechanisms by which viruses evolve to evade antibody-mediated neutralization. Also,
broadly neutralizing antibodies have helped to elucidate the conditions for protection
against HIV-1 infection (5, 29, 52, 58, 62, 74). By defining neutralizing epitopes on the
HIV-1 envelope glycoproteins, broadly neutralizing antibodies can serve as templates for
the design of subunit immunogens and help reveal the most vulnerable targets for
neutralization (95). Probing the antigenicity of vaccine candidates with broadly
neutralizing antibodies may have predictive value and provides a means for evaluating
the potential of candidate immunogens to in turn elicit neutralizing antibodies. Also,
broadly neutralizing antibodies have the potential to be used as therapeutic molecules, for
example, for the prevention of HIV- transmission from mother to infant.
Although in many HIV-infected patients, broadly neutralizing antibodies emerge
in the course of infection, the isolation and characterization of these reactivities remains a
major challenge. To date, only four broadly neutralizing antibodies have been identified:
The two gp120-directed antibodies IgG1b12 (21) and 2G12 (112), and the two gp41-
directed antibodies 2F5 (69) and 4E10 (18).
Two general strategies have been employed to identify novel broadly neutralizing
antibodies. The generation of monoclonal antibodies from fusions of B-cells derived from
HIV-1-infected patients has yielded the broadly neutralizing antibodies 2F5, 4E10, and
2G12. The broadly neutralizing antibody IgG1b12 has been identified from a phage-
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displayed antibody library that was generated from the bone marrow of a 31-year old
long-term nonprogressor with exceptionally high neutralizing antibody serum titers.
Antibody libraries generated from HIV-1-infected individuals have the advantage of
being enriched, or biased, for anti-HIV-1 directed antibodies. However, during any given
antibody response, a number of antigen-specific B-cell clones are selected and driven to
proliferate. In the course of this selection process, some antigen-specific reactivities
might become relatively underrepresented. Since the parameters selecting for B-cells to
mature and proliferate are affinity to the immunogen, not neutralizing potency, valuable
reactivities might be poorly represented in a biased library. Naïve libraries generated
from healthy uninfected donors, in contrast, are more likely to contain the full antibody
repertoire of the donor, although with anti-HIV reactivities at much lower frequencies. To
exploit the advantages of both types of libraries, one naïve and six biased libraries were
panned in an attempt to identify novel broadly neutralizing antibodies.
A number of different panning strategies was employed to more effectively select
for desired reactivities (Table 5). As a modification of panning A in which
proteoliposomes from only one viral isolate were used, panning B was performed with
envelope glycoprotein constructs derived from three different viral isolates. Thus, the
selection was intended to be focused on epitopes conserved among all different strains
while selecting against variable regions such as the variable loops V1, V2, and V3. The
sequence of envelope glycoproteins used in the subsequent rounds of panning was chosen
to be in the order of increasing neutralization-resistance (89.6, JR-FL, YU2). The
rationale was consistent with the hypothesis that neutralization-sensitivity correlates with
a more open conformation of the envelope glycoproteins.
For some panning experiments, epitope-masking was employed to selectively
block unwanted reactivities (33). In pannings C and D, an immunodominant gp41 cluster
II antibody that had previously been retrieved from the FDA-2 library was added to the
library during the selection to prevent the enrichment of this particular and other cluster II
reactivities. In panning C, monomeric YU2 gp120 was used to preabsorb the FDA-2
library and also added in excess to the library during selection. This blocking strategy
was aimed at the identification of antibodies specific for the trimeric envelope complex.
Other pannings involving epitope masking were panning F and G. For these experiments,
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a blocking Fab antibody, b6, was used at a concentration of 50µg/ml. This antibody binds
a very similar epitope on the CD4-binding site of envelope glycoprotein as does the
broadly neutralizing antibody b12 (Pantophlet et al., submitted). However, b6 does not
neutralize primary isolates efficiently. It is a longstanding puzzle which properties confer
the neutralizing phenotype of b12 when the epitopes of these two antibodies are so
similar. One hypothesis is that b6 may be able to bind two of the three envelope
glycoprotein spikes with high affinity, but is not able (possibly due to steric constraints)
to bind the third spike, leaving one spike to mediate viral binding and fusion. The b12
antibody, in contrast, may also be able to bind the third spike, thus rendering the envelope
glycoprotein nonfunctional. This hypothesis was supported by preliminary experiments
showing that there is a slight increase of binding when b12 is added to envelope
glycoproteins that have been saturated with b6 (data not shown) and provided the
rationale for this b6-blocking experiment.
There is some evidence suggesting that there are subtle antigenic differences in
the unprocessed gp160 envelope glycoprotein (cleavage-defective envelope glycoproteins
were used for pannings A-G and K) and the mature envelope glycoprotein. In pannings H
and I, proteoliposomes derived from the primary isolate 89.6 containing fully cleaved
envelope glycoprotein was used for selection. Only in the context of this particular viral
strain was the labile interaction of gp120 and gp41 subunits stable enough to produce
proteoliposomes containing about 60% cleaved envelope glycoprotein (data not shown).
Here we tested the hypothesis that mature envelope glycoprotein may identify other
reactivities than unprocessed envelope glycoprotein. Such antibodies would help in the
further elucidation of the antigenic differences of cleaved and uncleaved envelope
glycoprotein.
For the pannings F,G and H,I, a Fab version and a scFv version of the FDA-2
library were used for the panning with each antigen. Previous experiments have shown
that although both Fab and scFv libraries were generated from bone marrow of the same
patient, different clones can be selected with the same antigen. The two libraries may
therefore represent slightly different antibody repertoires. Pannings F, G, H, and I did not
yield any gp120 or gp41 binding reactivities. Possibly, the counterselection during
pannings F and G also competed with other CD4BS reactivities.
Discussion                                                                                                                               79
To test if envelope glycoproteins complexed to their receptors CD4 and CCR5
expose distinct, neutralizing epitopes that are recognized by antidodies, a panning was
performed with ternary complexes (panning D). Proteoliposomes were prepared
containing the second receptor CCR5. To these proteoliposomes, soluble trimeric
envelope glycoprotein complexed with soluble CD4 was bound. In this panning, only a
CD4-binding antibody could be retrieved. The most gp120 and gp41 binding reactivities
were identified in the pannings A and B. Of the broadly neutralizing Fabs CG5, CG9, and
CG21, CG5 was identified in panning A, CG9 was identified in pannings A and B, and
CG21 was identified in panning B (Table 6). It appears unlikely that there is a propensity
of any of the different panning strategies to selectively retrieve broadly neutralizing
antibodies better than any other. In particular, the experiments involving epitope masking
generally decreased the yield of gp120- and gp41-positive binders without identifying
different reactivities than the less complex pannings.
Interestingly, the panning of a naïve scFv library yielded only V3-loop directed
antibodies. The fact that no loop-directed reactivities were retrieved from the biased
libraries and only loop-directed reactivities from the naïve library reflects the general
dynamics of an antibody response during the course of HIV-1 infection. In the early
phases, when the virus encounters a naïve antibody repertoire, mostly strain-restricted,
loop-directed antibodies appear. This may be due to a higher precursor frequency of B-
cells capable of binding the charged, surface-exposed V3 loop structures. Only later in
the course of infection does this pattern change and mostly antibodies directed against
more conserved regions such as the CD4BS emerge. This is consistent with the
observation, based on sequence analysis of the neutralizing monoclonal antibodies that
recognize conserved HIV-1 epitopes, that antigen-driven affinity maturation is required
to generate these antibodies.
The Fab fragments CG5, CG9, and CG21 were found to exhibit broadly
neutralizing activity in HIV-1 single-round infection assays. The neutralization potency
and breadth of these Fabs is intermediate between that of the potent Fab b12 and the two
Fabs F91 and F105. When the neutralization efficiency of Fabs was compared to that of
the corresponding whole antibodies, a significantly higher neutralization potency of the
whole antibodies was consistently observed for b12 and F105, and with some viral
Discussion                                                                                                                               80
isolates with F91. The antibody input into the neutralization assay was normalized by
mass. Thus, more antigen-binding moieties per unit mass (at a ratio of 3:2) were added
with Fab than with IgG. And yet, the whole antibodies compensated this disadvantage by,
most likely, higher avidity. The Fab fragments CG5, CG9, and CG21 may therefore, too,
become more potent in neutralizing HIV-1 as whole antibodies. The IC50s defined here
might be underestimates of the neutralization potency of the physiologic whole
antibodies.
To date, the broad and potent neutralizing activity in the serum of the FDA-2
patient is unaccounted for. Identifying the nature of this activity would help to understand
the correlates of protection from progression to AIDS in general and in this particular
patient. The engineering of the three broadly neutralizing antibodies identified here is in
progress and may help to elucidate the broadly neutralizing reactivity in this patient.
4.4 Envelope glycoproteins deficient in T-helper epitopes
Escape of viruses from recognition by CD8+ T-cells has been well documented
(63). The effect of CD4+ T-helper cells on viral evolution, however, has been less well
studied. While CTLs directly exert immune pressure by killing virus-infected cells, the
selective pressure exerted by CD4+ T-helper cells by providing help necessary for both
CTL and antibody responses is less direct. For HIV-1, the impaired CD4+ T-helper cell
reponses due to progressive depletion has been suggested to be a major mechanism of
HIV-1 escape from an efficient host immune response (34, 88). It could be shown in a
transgenic system for LCMV infection that viruses also evade immune recognition by
CD4+ T-helper cells (27). Also, the emergence of altered peptide ligands in Gag that fail
to stimulate CD4+ T-helper cells have been described in asymptomatic HIV-1-infected
patients (46). Here, we present data that suggests the escape from T-helper cell
recognition in the context of the HIV-1 envelope glycoprotein gp120.
Core gp120 derived from two HIV-1 primary isolates, but not from TCLA
isolates, are defective in their ability to raise envelope glycoprotein-directed antibodies.
Since this effect was not readily observable in TCLA isolate-derived core gp120
envelope glycoproteins, it is likely a direct consequence of the antibody-mediated
immune pressure exerted on the primary isolate in vivo. The addition of the heterologous
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T-helper epitope PADRE to the YU2 primary isolate core gp120 fully restored its
immunogenicity as determined by antibody generation, suggesting that the observed
defect of core gp120 to elicit antibodies was due to a lack of T-helper epitopes. The T-
helper epitope deficiency of primary isolate core gp120s was initially observed in two
strains of mice. The limited MHC class II diversity in these animals, however, warranted
the extension of these experiments to outbred animals. A general mechanism of viral
escape should manifest itself in an outbred population with a diverse MHC class II
repertoire. The phenomenon previously observed in mice also translated into outbred
rabbits. As expected in the more diverse array of MHC class II alleles present in the
outbred rabbits, the lack of antibody elicitation by the YU2 core gp120 was observable
but not as absolute a phenomenon as observed in mice. Interestingly, one animal in five
inoculated with YU2 core gp120 generated anti-gp120 IgG titers that were similar to the
titers detected in rabbits inoculated with the YU2 core-PADRE gp120. This finding
indicates that the absence of an anti-gp120 response in the other animals of this group is
most likely due to a difference in their MHC class II alleles, not to a quantitative
difference in the core gp120 and core-PADRE gp120 inoculated into the two
experimental groups. The similar titers of T-cell-independent anti-gp120 IgM responses
raised with core gp120 and core-PADRE gp120 also indicate that the input protein was
similar for the two groups. Although T-helper epitope deficiency was observed in the
context of mouse and rabbit MHC, it suggests that viral evolution of the gp120 envelope
glycoprotein to diminish help in the context of human MHC may have occurred.
The T-helper epitope deficiency of primary isolates was observed in the context
of core gp120 envelope glycoproteins deleted of variable loops V1 and V2, and parts of
the C1 and C5 regions. These cores represent an approximation of the gp120
determinants that are minimally required for basic function, that is the binding of receptor
and coreceptor. The variable loops V1 and V2 are dispensible for viral entry and
replication. The V3 loop, however, is required for the binding of coreceptors during the
entry process. The core gp120 format was chosen for this study initially to test whether
envelope glycoproteins deleted of the variable loops V1 and V2 would better generate
broadly neutralizing antibodies by focusing the immune response on the conserved
receptor binding sites and removing steric barriers that may impede access of B-cell
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receptors to these regions. For the study of T-helper epitope deficiencies, this system has
advantages over the use of full-length gp120. Limiting the protein determinants to
conserved, functionally important regions allowed us to investigate specifically the
protein regions that are shared by most viral isolates. These conserved regions have
encountered and adapted to a large array of host MHC class II alleles during repeated
evolution of virus and immune system in multiple hosts. Any attempt of the virus to
evade recognition by the host’s polymorphic immune presentation system, therefore,
most likely manifests itself in the core gp120. In the core, functional constraints limit the
ability of the virus to mutate in response to the host’s MHC repertoire, whereas the
variable loops V1/2 and parts of V3 can tolerate extensive variation. Therefore, effects
seen in the full-length gp120 context might simply reflect adaptation of one particular
viral isolate to one host MHC class II allele through changes in the variable loops.
Although such changes in the variable loops would also strongly indicate the escape from
T-helper cell recognition, they would be difficult to detect unless they were observed in a
matched virus/MHC class II system in which the virus sequence as well as the MHC
class II alleles the virus encountered are known. For the YU2 and JR-FL envelope
glycoproteins, the MHC background of the respective host has not been determined.
A number of studies have focused on the identity and localization of T-helper
epitopes in HIV-1 proteins (28, 100, 107, 114). For the primary clade B isolate 1007 and
the primary clade C isolate UG, three hotspots of H2-IAb-restricted helper epitopes in the
gp120 envelope glycoproteins have been described in the same animal model that was
used here (C57BL/6) (107). These hotspots locate to V2-C2, V3, and V4-C4, with most
of the epitopes found in C2 and V3 (22 of 26 total). If these data are interpreted in the
context of the core gp120 used here, deletion of the V1 and V2 loop in these viral isolates
would have removed only two of 26 helper epitopes. Assuming that the distribution of
helper epitopes along hotspots is similar in other primary isolates, the core gp120
molecules used here would not have been rendered help-deficient through deletion of the
V1 and V2 loop alone. Helper deficiency brought about by simply deleting the V1 and
V2 loops, therefore, appears unlikely to account for the profound deficiency in T-helper
epitopes in the primary isolate core gp120s used here. In the study by Surman (107),
gp120 T-helper epitopes were suggested to be limited by the exposure on the three
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dimensional structure of the protein. A number of T-helper epitopes identified in this
study do not appear to function in the primary core gp120 molecules used in our study.
As reported, the YU2 and JR-FL core gp120 appear to be profoundly deficient in T-
helper epitopes. The differences between our results and the Surman study may be
accounted for by several factors. The immunization scheme in the Surman study utilizes
DNA, vaccinia virus, and protein in Freund's adjuvant, whereas our study utilizes protein
in the nondenaturing Ribi adjuvant. The in vitro stimulation of CD4+ T-helper cells may
not fully recapitulate the in vivo situation. In addition, the Surman study does not
discriminate helper responses of the TH1 and TH2 subtype, whereas the antibody readout
of our study is biased toward detecting T-helper responses of the TH2 type. Also, the
observed T-helper epitope deficiency in primary isolate core gp120s observed here may
be more apparent in our study as it was observed relative to TCLA-derived envelopes.
One obvious caveat to our study is that the core gp120s used here were selected
against human MHC alleles whereas the T-helper epitope deficiency was observed in a
non-human background. Although these findings could be extended to outbred animals,
this system may yet not be the most faithful to study viral evolution against a human
MHC background. However, we observed the same helper epitope deficiency of primary
isolate core gp120 in outbred animals, suggesting that the reduced immunogenicity may
have been influenced by viral evolution in the context of human host MHC. For a chronic
virus such as HIV-1, virtually any means that reduces the viral immunogenicity will be of
selective advantage for the virus.
Escape from recognition by CD4+ T-helper cells of primary isolate HIV-1
envelope glycoproteins has important implications for the design of subunit vaccines. It is
becoming increasingly clear that TCLA-derived envelope glycoproteins are not optimal
as subunit vaccines for the generation of neutralizing antibodies. Based upon our
observations, however, the use of primary isolate-derived envelope glycoproteins as
subunit vaccines may be complicated by the relative deficiency in T-cell helper epitopes.
The addition of heterologous helper epitopes, as described here, may be necessary to
elicit titers high enough for the efficient neutralization of challenge virus. A heterologous
helper epitope such as PADRE might be highly effective in generating persistent,
circulating antibodies in a large population with diverse MHC class II alleles. To
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facilitate the elicitation of a recall response when the vaccinated individual encounters
challenge virus, however, the use of additional homologous HIV-1-derived helper
epitopes would be warranted.
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5 Summary
Solid-phase proteoliposomes containing HIV-1 envelope glycoproteins faithfully
mimic the trimeric envelope glycoprotein complex as it is found on the virus. These
novel envelope glycoprotein formulations contain high concentrations of affinity-purified
envelope glycoprotein in a physiologic membrane setting. The changes in the envelope
glycoproteins necessary for retaining native trimeric structure in this format are minimal.
These proteoliposomes have improved immunogenic properties and elicit titers of
anti-envelope glycoprotein antibodies in mice and rabbits comparable to those elicited by
a 5-fold greater amount of soluble envelope glycoproteins. Two different trimeric
envelope glycoprotein formulations (PLs and YU2gp140-GCN4) elicit neutralizing
antibodies better than monomeric gp120. Proteoliposomes are more efficient in eliciting
neutralizing antibodies with some breadth than monomeric gp120 in rabbits. If dose
limitations in this format can be overcome, proteoliposomes may prove to be an advance
over current envelope-based immunogens. Soluble trimeric envelope glycoprotein
ectodomain constructs (YU2 gp140-GCN4) elicit broadly neutralizing antibodies in
rabbits, extending previous findings in mice to a more diverse MHC background.
Three Fab antibody fragments binding to the CD4BS of gp120 have been
identified from phage-displayed antibody libraries with proteoliposomes. These
antibodies display broad and potent neutralization of a number of HIV-1 molecular
clones. Comparison of the neutralizing potency of other CD4BS Fab fragments with the
corresponding whole antibodies suggests that the three identified CD4BS Fabs might
significantly gain neutralization potency as full antibodies. They may represent new
members of the small and elusive family of HIV-1 broadly neutralizing antibodies.
Core gp120 envelope glycoproteins derived from primary isolates are deficient in
T-helper epitopes. Viral evolution may have selected for envelope glycoproteins that
elicit suboptimal helper responses. Escape from CD4+ T-helper cell recognition may be
yet another immune escape mechanism of HIV-1.
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Abbreviations
α anti
∆ delta
µg microgram
µl microliter
µM micromolar
AIDS Acquired Immunodeficiency Syndrome
BME beta mercaptoethanol
BSA bovine serum albumin
CD4 cluster of differentiation
CD4BS CD4 binding-site
CD4i CD4-induced
CDR complementarity determining region
CMV cytomegalovirus
CT cytoplasmic tail
DMSO dimethyl sulfoxide
DTT dithiothreitol
ECL enhanced chemiluminescence
E. coli Escherichia coli
EDTA ethylenediaminetetraacetic acid
ELISA enzyme-linked immuno-sorbent assay
FACS fluorescence-activated cell sorter
FCS fetal calf serum
FITC fluorescein isothiocyanate
g gram
GFP green fluorescent protein
gp glycoprotein
h hour
HAART highly active anti-retroviral therapy
HIV Human Immunodeficiency Virus
IC inhibitory concentration
IPTG isopropyl β-D-thiogalactopyranoside
kDa kilodalton
kb kilobase
l liter
LTNP long-term nonprogressor
LTR long terminal repeat
m milli
M molar
MHC major histocompatibility complex
Mg milligramm
min minutes
ml milliliter
MOI multiplicity of infection
Abbreviations                                                                                                                         
MOPS 3-N-morpholino-propansulfonic acid
MPL monophosphoryl lipid A
OD optical density
O/N over night
PADRE pan-DR helper epitope
PAGE polyacrylamide gelelectrophoresis
PBMC peripheral blood mononuclear cells
PMSF phenylmethylsulfonylfluoride
PBS phosphate buffered saline
PCR polymerase chain reaction
PE phycoerythrin
PLs proteoliposomes
RT room temperature
s second
SB super broth
sCD4 soluble CD4
scFv single-chain Fv
SDS sodium-dodecylsulfate
SIV Simian Immunodeficiency Virus
TCID tissue culture infectious dose
TCLA T-cell line adapted
TCR T-cell receptor
TDM trehalose dicorynomycolate
VLP virus-like particle
WT wild-type
